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ABSTRACT
Alcohol Modulation of Dopamine Release
Nathan Dan Schilaty
Department of Physiology and Developmental Biology, BYU
Doctor of Philosophy
The mesolimbic dopamine (DA) system projects from the ventral tegmental area (VTA)
to structures associated with the limbic system, primarily the nucleus accumbens (NAc). This
system has been implicated in the rewarding effects of drugs of abuse. Many drugs of abuse act
in the VTA, the NAc, or both. Dopamine neurons in the VTA that project to the NAc, and the
GABA neurons that inhibit DA neurons locally in the VTA or project to the NAc, play an
important role in mediating addiction to various drugs of abuse, in particular alcohol. There is a
growing body of evidence of co-dependence of nicotine and ethanol drug abuse. Given this
evidence, it is possible that both ethanol and nicotine target similar receptors in the NAc. The
GABAA and GABAB receptors have also been implicated in the modulation of ethanol’s
reinforcing properties (Anstrom, Cromwell, Markowski, & Woodward, 2003; Besheer, Lepoutre,
& Hodge, 2004; Colombo et al., 2000; Moore & Boehm, 2009; Stromberg, 2004; Walker &
Koob, 2007). Thus, there is a growing literature suggesting that GABA receptors are implicated
in ethanol reward. In these studies, we evaluated the possibility of co-dependence of nicotine
and ethanol by activity on a similar receptor in the NAc. In addition, we evaluated the role of
GABA modulation of DA release, in particular GABAA receptors and GABAB receptors, in
modulating DA release in the NAc with acute ethanol exposure. The rationale for this study was
predicated on the belief that advancement in the understanding of the brain mechanisms
underlying the recreational use and abuse potential of alcohol will pave the way for more
effective treatment strategies that could reverse alcohol dependence and co-dependence and save
lives and resources throughout the world.
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CHAPTER 1: Introduction
The Economic and Social Costs of Alcohol Abuse
Widespread illicit and legal drug abuse takes an enormous toll on individual human
suffering and society. The consequences of drug abuse include: lost job productivity;
squandered earnings; rising healthcare costs; incarcerations; investigations; vehicular accidents;
domestic and non-domestic violence; premature death; and the breakdown of the family unit
(“National Survey on Drug Use and Health”). The economic and societal implications arising as
direct or indirect result of drug abuse consumption are staggering. For example, in 2006 it was
determined that there were at least 15.3 million people in the U.S. that met the criteria for alcohol
abuse or addiction (Gordis), and that the direct costs alone related to alcohol abuse range as high
as $185 billion in the U.S. annually.
Often taken in concert (Miller & Gold, 1998), the use of alcohol and tobacco are leading
causes of preventable death in the United States (Danaei et al., 2009). Approximately 80% of
alcoholics are also smokers (Hendrickson, Guildford, & Tapper, 2013; Taylor, Steffensen, &
Wu, 2013), and heavy smokers are ten times more likely to be alcoholics (DiFranza & Guerrera,
1990). While smoking rates in the general population have decreased in recent decades, the use
of nicotine has remained high (approximately 70-75%) in individuals who regularly use alcohol
(Hendrickson et al., 2013; Meyerhoff et al., 2006).

The Mesolimbic Dopamine System
The mesolimbic dopamine (DA) system in the mammalian brain projects from the ventral
tegmental area (VTA) to structures associated with the limbic system, primarily the nucleus
accumbens (NAc). This system has been implicated in the rewarding effects of drugs of abuse
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(Blackburn, Phillips, Jakubovic, & Fibiger, 1986; Koob, 1992; McKinzie, Rodd-Henricks,
Dagon, Murphy, & McBride, 1999; Pierce & Kumaresan, 2006; Wise, 1996; Wise & Bozarth,
1987). The VTA is a relatively amorphous midbrain structure that contains at least three neuron
types: Primary type or DA neurons that project to the NAc; Secondary type or GABA neurons
that may participate in local circuitry (acting to inhibit DA neurons) or project to other brain
regions: and a population of glutamatergic (GLUergic) neurons (Yamaguchi, Sheen, & Morales,
2007). Dopamineric neurons represent ~ 65 %, GABAergic neuron ~ 30 %, and GLUergic
neurons represent ~ 5 % of the neurons in the VTA (Margolis et al., 2006; Margolis, Toy,
Himmels, Morales, & Fields, 2012). The NAc, which is part of the ventral striatum, can be
divided into two structures: the core, and the shell; each have different morphology and function.
Although both pertain to reward processing, the shell is primarily concerned with motivation of
reward whereas the core is involved with the motor aspects of reward. The shell portion of the
NAc appears to be more important than the core for drug reward, as the medial VTA, running
rostral to caudal, seems to hold the greatest concentration of DA neurons that project to the NAc
(Ikemoto, 2007).
Many drugs of abuse act in both the VTA and the NAc. However, most rats and mice
will self-administer cocaine (David et al., 2004, Rodd et al., 2005), ethanol (Gatto et al., 1994,
Rodd-Henricks et al., 2000), nicotine (Museo and Wise, 1981, Laviolette and van der Kooy,
2003), cannabinoids (Zangen et al., 2006), and opiates (Bozarth & Wise, 1981; David & Cazala,
1994; Devine & Wise, 1994; Welzl, Kuhn, & Huston, 1989) into the VTA, suggesting that DA
neurons in the VTA that project to the shell of the NAc, and the GABA neurons that may inhibit
DA neurons locally in the VTA, play an important role in mediating addiction to various drugs
of abuse.
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Dopamine release in target areas of the mesolimbic system has been implicated in the
rewarding properties of drugs of abuse, including alcohol (Blackburn et al., 1986; Koob, 1992;
Wise, 1996; Wise & Bozarth, 1987). The emerging view is that the dysregulated homeostasis
that accompanies the development of drug addiction may result from experience-dependent
neuroadaptations that hijack normal synaptic transmission in the mesolimbic DA system (Hyman
& Malenka, 2001; Hyman, Malenka, & Nestler, 2006; Kauer & Malenka, 2007; Nugent &
Kauer, 2008).

The Cycle of Addiction and Current Treatment Strategies
A major goal of research on alcoholism is to characterize the critical neural substrates
that are most sensitive to alcohol, adapt in association with chronic consumption and drive
subsequent alcohol-seeking behavior. A significant need exists for understanding how alcohol is
affecting DA transmission in the mesolimbic system. A basis for this study is predicated on the
belief that advancement in the understanding of the brain mechanisms underlying the
recreational use and abuse potential of alcohol will pave the way for more effective treatment
strategies that could reverse alcohol dependence and save lives and resources throughout the
world.
Addicts continue their cycle of abuse as a result of low DA levels in pleasure areas of the
brain. These low levels of DA result in feelings of anxiety and dysphoria, impelling subsequent
drug seeking and taking (Di Chiara, Bassareo, and others). Systemic administration of most
drugs of abuse briefly enhances DA levels. It is likely that the short-lived enhancement of DA
release in the NAc and other pleasure system structures is what underlies the euphoric aspect of
psychoactive drugs and natural rewarding behaviors (eating, drinking, and sex). However, drugs
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overwhelm this system and tolerance/dependence result in subsequent drug taking, ultimately
causing persistent dysfunctional DA homeostasis.
Conventional therapies for addiction include self-help groups, drug therapy, and
substitution therapy. The search for effective medications for substance abuse and addiction has
been difficult as these medications produce akinesia, deficits in cognitive performance, and
disrupt natural pleasure sensation (Gonzalez, Oliveto, and Kosten). These side-effects result in a
lack of patient compliance and poor prognoses.

Clinical Therapeutics for Addiction
Given my clinical background, I am very interested in discovering viable treatments for
addiction, in particular alcohol addiction. There are currently no known effective substances that
can assist in alleviating the hedonic response of an addict. Replacement therapies exist, but as
previously mentioned, they do little good as the addict is still addicted to some form of drug.
Nutraceutical therapy would be a viable option if it demonstrated promise in raising DA levels to
overcome the hedonic response and was non-addictive. After some research of various
compounds and upon a review of the scientific literature, a possible candidate emerged:
baicalein. Baicalein is an isoflavone found in the plant Scutellaria baicalensis (also known as
Chinese Skullcap). Mainly found in the roots of the plant, it has been isolated and tested
scientifically with amphetamines (Wu, Shen, Wang, Chi, & Yen, 2006) with successful results
on counteracting neurotoxicity and protecting the dopamine transporter (DAT) from destruction
(Wu et al., 2006). It is conceivable that this compound could be useful as a clinical method for
restoring DA homeostasis in the brains of human drug addicts if the mechanism by which it
operates in the brain can be determined.
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GABA and Glutamate Synaptic Transmission and Alcohol Reward
A major goal of basic research on alcoholism is to understand the neural basis of alcohol
use and the pathological progression to alcohol dependence (Gilpin & Koob, 2008). The
compulsion to consume alcohol stems from both its positive reinforcing properties (e.g.
anxiolytic and euphoric effects) and its negative reinforcing properties (e.g. aversive withdrawal
symptoms that result from abstinence) (Koob, Rassnick, Heinrichs, & Weiss, 1994). The
prevailing view is that synaptic transmission in the central nervous system is depressed by acute
intoxicating doses of ethanol (Ariwodola et al., 2003; Berry & Pentreath, 1980; Bloom et al.,
1984; Deitrich, Dunwiddie, Harris, & Erwin, 1989; Shefner, 1990; Siggins et al., 1987), which
might result from either an attenuation of excitatory glutamate (GLU) synaptic transmission
(Lovinger, White, & Weight, 1989; D.M. Lovinger, G. White, & F.F. Weight, 1990; Nie, Yuan,
Madamba, & Siggins, 1993; Roberto et al., 2004; White, Lovinger, & Weight, 1990) and/or an
enhancement of inhibitory γ-aminobutyric acid (GABA) synaptic transmission (Deitrich et al.,
1989; Harris & Allan, 1989; Roberto, Madamba, Moore, Tallent, & Siggins, 2003). There is
compelling evidence that ethanol can alter GLU N-methyl-D-aspartate (NMDA) receptors (P.
Hoffman, Rabe, Moses, & Tabakoff, 1989; P. L. Hoffman & Tabakoff, 1993; Lima-Landman &
Albuquerque, 1989; Lovinger et al., 1989; D. M. Lovinger, G. White, & F. F. Weight, 1990;
D.M. Lovinger et al., 1990; Roberto et al., 2004), that low doses of ethanol may interact with
inhibitory subtype GABAA receptor (GABAAR) complexes (Allan & Harris, 1986; Liljenquist &
Engel, 1982; Mihic & Harris, 1996; Suzdak et al., 1986; Ticku, Lowrimor, & Lehoullier, 1986),
and that ethanol can interact with neuromodulators such as neurosteroids (Brot, Akwa, Purdy,
Koob, & Britton, 1996; Kumar, Fleming, & Morrow, 2004; Lambert, Peters, & Cottrell, 1987;
Simmonds, 1991; Wieland, Belluzzi, Stein, & Lan, 1995). In addition to ethanol acting via

5

GABAARs, the GABAB receptor (GABABR) has been implicated in the modulation of ethanol’s
reinforcing properties as well (Anstrom et al., 2003; Besheer et al., 2004; Colombo et al., 2000;
Moore & Boehm, 2009; Stromberg, 2004; Walker & Koob, 2007). Thus, there is a growing
literature suggesting that both GABAA and GABABRs are implicated in ethanol reward and
further understanding of the underlying mechanisms is necessary.

GABAA and GABAB Receptor Characteristics
Regarding GABA synaptic transmission, GABA activation of GABAA and GABAB
receptors causes hyperpolarization of neuronal membranes and inhibition of neuronal
excitability, but their mechanisms differ markedly. GABA receptors are classified into
ionotropic and metabotropic subtypes (Chebib & Johnston, 1999). Both the GABAARs and
GABAC receptors (GABACRs) are the ionotropic subtypes while the GABABRs is the
metabotropic subtype (G-coupled protein receptor) (Bormann, 2000). Ionotropic receptors
contain a gating mechanism that is activated by specific ligands. When these ligands bind to the
GABA receptor subunits, a Cl- ion inwardly passes through the channel, causing a fast synaptic
inhibition to the respective neuron (Chebib & Johnston, 1999). Metabotropic receptors, when
activated by a specific ligand, undergo a morphological change that activates a G-protein and
then initiates intracellular cascading mechanisms to occur that can affect many cellular functions
such as gene transcription, protein production, phosphorylation, and neurotransmitter release.
GABAARs are widely distributed throughout the nervous system, both centrally and
peripherally, and are pentameric receptors that contain a combination of receptor subunits (α1-α6,
β1-β3, γ1-γ3, δ, ε, θ, ρ1-ρ3, or π) with the αβγ combination being the most typical of the
GABAARs. As GABAARs are regulatory to the entire nervous system, the pharmacology of
GABAARs has been widely studied and is well known and classified.
6

GABACRs, although ionotropic and pentameric like the GABAAR, were previously
classified separately as they contain only ρ-subunits (Amin & Weiss, 1994) and were known to
be found primarily in the retinal neural structures. The ρ-subunits homo-oligomerize to form
GABAAρ receptors [formerly classified as GABACRs, (Bormann, 2000)]. Interestingly,
although controversial, ρ-subunits are known to co-assemble with the GABAAR subunits
producing receptors with unique properties (Milligan, Buckley, Garret, Deuchars, & Deuchars,
2004) and the possibility of ρ-subunits co-assembling with other GABAAR subunits continues to
be theorized (Martinez-Delgado, Estrada-Mondragon, Miledi, & Martinez-Torres, 2010). To
make matters even more interesting, some have recently theorized that some atypical GABAAR
characteristics in the nervous system may be due to integration of the ρ-subunit into the
GABAAR (Martinez-Delgado et al., 2010; Milligan et al., 2004). Thus, it appears that the
classification of the once distinct GABACR is further being merged into the single ionotropic
GABAAR classification.
GABABRs are seven transmembrane receptors that are also widely distributed throughout
the central and peripheral nervous system where they regulate synaptic transmission and signal
propagation by controlling the activity of voltage-gated calcium and inward-rectifier potassium
channels (Schwenk et al., 2010). They are heteromeric proteins composed of a both B1 and B2
subunits. Homomeric possibilities of GABABRs has not been successfully proven (Benke,
Michel, & Mohler, 2002; Bettler, Kaupmann, Mosbacher, & Gassmann, 2004), although
theorized (Calver et al., 2000), and atypical characteristics of GABABRs are not documented.

A Role for Dopamine in Alcohol Reward
Both in vivo (Gessa, Muntoni, Collu, Vargiu, & Mereu, 1985) and ex vivo (Brodie &
Appel, 1998; Brodie, Shefner, & Dunwiddie, 1990) studies indicate that acute ethanol increases
7

DA release in limbic structures and/or VTA DA firing rates, and that withdrawal from chronic
ethanol reduces DA firing rate and release in the NAc (Diana, Pistis, Carboni, Gessa, & Rossetti,
1993). Furthermore, pharmacological or genetic manipulations that diminish DA activity inhibit
ethanol consumption and preference (El-Ghundi et al., 1998; Ikemoto, McBride, Murphy,
Lumeng, & Li, 1997; Phillips et al., 1998), conditioned place preference (Cunningham et al.,
2000; Risinger, Freeman, Greengard, & Fienberg, 2001), the acquisition of ethanol selfadministration (Risinger, Freeman, Rubinstein, Low, & Grandy, 2000), and ethanol preference
and sensitivity (Phillips et al., 1998).

Ethanol Modulation of Dopamine Release: Microdialysis Versus Voltammetry
Dopamine release, as measured by microdialysis and fast-scan cyclic voltammetry
(FSCV), exhibit disparate results with ethanol and nicotine studies in the NAc. These
neurochemical studies provide compelling, but complicated, evidence regarding ethanol effects
on DA transmission (Brodie & Appel, 1998; Gysling & Wang, 1983; Mereu, K-W., Gessa, Naes,
& Westfall, 1987). Microdialysis studies typically demonstrate a rise in DA levels while
voltammetry studies show a fall in evoked DA responses by both acute nicotine and ethanol
(Budygin et al., 2001; D. L. Robinson, E. C. Howard, S. McConnell, R. A. Gonzales, & R. M.
Wightman, 2009; Yorgason, Ferris, Steffensen, & Jones, 2013; Zhang et al., 2009). For
example, most microdialysis studies have demonstrated that ethanol enhances DA release at
moderate-to-high ethanol concentrations (Blomqvist, Ericson, Engel, & Söderpalm, 1997),
though others have reported no effect or DA reductions at high ethanol doses (Blanchard,
Steindorf, Wang, & Glick, 1993). Dopamine levels also increase in association with ethanol
self-administration (Ericson, Blomqvist, Engel, & Söderpalm, 1998; Weiss, Lorang, Bloom, &
Koob, 1993). However, in vitro studies have shown that ethanol decreases K+-evoked DA
8

release from synaptosomes (J. J. Woodward, Machu, & Leslie, 1990) and NMDA-stimulated DA
release from striatal slices (J. J. Woodward & Gonzales, 1990).
In FSCV studies, wherein both release and uptake of DA can be evaluated, acute ethanol
decreases DA release in freely-behaving rats [IC50 of 2.0 g/kg; (Budygin et al., 2001)] and in
mouse and rat brain slices (Schilaty et al., 2014), without affecting uptake (S. R. Jones, Mathews,
& Budygin, 2006)[but see Robinson, Volz, Schenk, and Wightman (2005)]. Interestingly, while
1-2 g/kg ethanol has enhancing effects on spontaneous DA release, as measured with
microdialysis, it has heterogeneous effects on rapid DA release, increasing spontaneous DA
transient frequency (Donita L. Robinson, Elaina C. Howard, Scott McConnell, Rueben A.
Gonzales, & R. Mark Wightman, 2009), but decreasing electrically stimulated DA amplitude (S.
R. Jones et al., 2006), as measured by FSCV, suggesting that the effects of increased tonic firing
contribute more to the microdialysis-measured DA levels compared to decreased phasic release
of ethanol on DA release in the NAc (Donita L. Robinson et al., 2009). The emerging picture is
that ethanol enhances DA neuron activity at moderate to high doses, and spontaneous DA release
at moderate to high doses, but exerts an inhibitory effect on phasic DA release at moderate to
high doses via its effects on DA terminals.
The disparity between these techniques is due, in part, to differences in measurements of
tonic versus phasic DA release (D. L. Robinson et al., 2009). We have recently demonstrated
that ethanol preferentially inhibits high-frequency phasic release, but not low-frequency “tonic”
release (Yorgason et al., 2013). Similarly, nicotinic mechanisms regulate the frequency
dependence of DA release, albeit in a different direction, with greater DA release under phasiclike conditions, and decreased release under tonic-like stimulations (Exley, Clements, Hartung,
McIntosh, & Cragg, 2008).

9

Mechanism of Action of Ethanol Effects on Dopamine Release
One population of GABA neurons in the VTA has projections to the NAc (M. T. Brown
et al., 2012b; van Zessen, Phillips, Budygin, & Stuber, 2012). It has recently been theorized that
due to the high percentage of co-dependence with nicotine and ethanol, they may act on similar
targets in the brain, specifically nicotinic acetylcholine receptors (nAChRs) on presynaptic
GABAergic neurons or DAergic terminals (Hendrickson et al., 2013; Taylor, Steffensen, et al.,
2013). Ethanol appears to activate DAergic neurons in the VTA through an interaction at
nAChRs (Soderpalm, Lof, & Ericson, 2009). To date, there have not been any studies on the
possible regulation of nicotine or ethanol on either of these terminals in the NAc via activation of
α6*-nAChRs.
Despite the many studies implicating the mesolimbic DA system in ethanol reward,
consumption and alcoholism [for recent review see Soderpalm and Ericson (2012)], there are
relatively few pharmacological studies elucidating the mechanism of action of ethanol effects on
this system. Dopamine release is controlled or modulated by several neurotransmitters including
GABA, GLU and glycine (GLY), metabolites including acetaldehyde (Melis, Diana, Enrico,
Marinelli, & Brodie, 2009), enzymes including catalase (Zimatkin, Pronko, Vasiliou, Gonzalez,
& Deitrich, 2006), receptors including the family of cysteine-loop gated ion channels including
nicotinic receptors (Soderpalm, Ericson, Olausson, Blomqvist, & Engel, 2000), GLYRs,
GABAARs and serotonin receptors (5-HT3Rs), as well as the DA transporter (DAT) and D2
receptors, yet the elucidation of the molecular mechanisms by which ethanol affects reward in
the context of the DA system remains elusive. As mentioned above, there is fairly compelling
evidence based on microdialysis studies that ethanol enhances DA neurotransmission in the
mesolimbic system via enhancement of DA neuron activity in the VTA. However, DA neurons
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are excited by ethanol only at high-lethal doses of ethanol [in vivo (Gessa et al., 1985) and ex
vivo (Brodie & Appel, 1998; Brodie et al., 1990)].
Recently, the Luscher lab has shown evidence that VTA GABA neurons project to the
NAc and contact cholinergic interneurons (M. T. Brown et al., 2012a). A subset of GABAergic
NAc medium spiny neurons (MSNs), which also express DA D1 receptors, sends a reciprocal
projection back to the VTA (Heimer, Zahm, Churchill, Kalivas, & Wohltman, 1991; Kalivas,
Sorg, & Hooks, 1993; Nauta, Smith, Faull, & Domesick, 1978; Tripathi, Prensa, Cebrian, &
Mengual, 2010; Usuda, Tanaka, & Chiba, 1998). This reciprocal loop between GABA neurons
in the VTA and GABA neurons in the NAc is believed to provide inhibitory feedback to regulate
DA neuron activity (Einhorn, Johansen, & White, 1988; Rahman & McBride, 2000) via VTA
GABA neurons (Xia et al., 2011). Figure 1 shows the synaptic hodology of VTA GABA
neurons, including the reciprocal loop between the VTA and NAc, as well as the key receptors
involved in ethanol actions on VTA GABA and NAc MSNs. The Steffensen lab has previously
demonstrated that both of these GABA neurons are inhibited by physiologically-relevant doses
of ethanol, and that ethanol inhibition of NMDA receptor-mediated GLU transmission is blocked
by GABABR antagonists (Steffensen et al., 2000). Thus, the mechanism underlying alcoholinduced inhibition of DA transmission is controversial.
Indeed, the neuroadaptions that occur in the brain in association with alcohol dependence
may result from plasticity associated with persistent activation of inhibitory GABA and/or
excitatory GLU synaptic transmission (Nugent & Kauer, 2008). One speculation for how drugs
of abuse might result in dysregulation of mesolimbic DA homeostasis is that repeated exposure
results in synaptic plasticity, which is the net effect of potentiation of GLUergic (Bonci &
Malenka, 1999; Overton, Richards, Berry, & Clark, 1999) and GABAergic synapses (Nugent &
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Kauer, 2008) on DA neurons in the VTA. The Steffensen lab has previously reported in multiple
studies that GABA neuron firing rate is inhibited by ethanol in rats in vivo with an IC50 of 1.0
g/kg (Gallegos, Criado, Lee, Henriksen, & Steffensen, 1999; K. H. Ludlow et al., 2009; S. C.
Steffensen et al., 2009; S.H. Stobbs et al., 2004). Most importantly, they have shown that VTA
GABA neurons become tolerant to repeated exposure to ethanol and evince marked
hyperexcitability during withdrawal from chronic ethanol, suggesting that these neurons are
adaptable substrates to alcohol dependence. The hyperexcitability of VTA GABA neurons
evident during withdrawal from chronic ethanol appears to result from cumulative short-term
withdrawals from ethanol. Interestingly, ethanol suppression of NMDA receptor-mediated GLU
synaptic transmission, which is implicated strongly in most forms of neural plasticity, appears to
be mediated by presynaptic GABABRs on GLU terminals to VTA GABA neurons and NAc
MSNs (Steffensen, Nie, Criado, & Siggins, 2000). Thus, ethanol reduction of VTA GABA
neuron activity appears to be mediated in part by NMDA receptors, and it is reasonable to
assume that they would play a role in short-term plasticity to ethanol exposure and ultimately
adaptations in DA release.

Rationale for Proposed Studies
Dr. Steffensen’s lab has shown in multiple reports that acute ethanol inhibits the firing
rate of VTA GABA neurons in rats with an IC50 of 1.0 g/kg (Gallegos et al., 1999; K. H. Ludlow
et al., 2009; S. C. Steffensen et al., 2009; S.H. Stobbs et al., 2004), which is one order of
magnitude more sensitive than ethanol effects on DA neurons (Brodie & Appel, 1998; Gysling &
Wang, 1983; Mereu et al., 1987). In addition, his lab has reported that VTA GABA neurons are
even more sensitive to acute ethanol in mice, characterized by an IC50 of 0.25 g/kg (Steffensen et
al., 2010). Most importantly, tolerance accrues to ethanol inhibition of VTA GABA neuron
12

Figure 1: Theoretical Framework for Proposed Studies on Ethanol Effects on Dopamine Release in the
Nucleus Accumbens. This model is based on general knowledge, our previous studies, and on preliminary
findings described below in the Approach section. Dopamine neurons in the VTA project to the NAc via
the medial forebrain bundle (MFB). We have shown previously that VTA GABA neurons project to the
cortex ((Steffensen, Svingos, Pickel, & Henriksen, 1998); not illustrated here) and others have shown that
they project to the NAc (Carr & Sesack, 2000; Margolis, Lock, Hjelmstad, & Fields, 2006; Van Bockstaele
& Pickel, 1995). Direct pathway NAc MSNs expressing D1 receptors project back to the VTA and inhibit
VTA GABA neurons. We propose that VTA GABA neurons contact DA terminals as illustrated and
inhibit DA release via GABABRs. We have previously demonstrated that ethanol inhibition of VTA
GABA neurons and NAc MSNs is mediated through GABABRs. While there are similarities between VTA
GABA and NAc MSNs their GLU and GABA and D1 and D2 receptor hodology differ appreciably. The
focus of this study is to evaluate interactions between GABABRs in mediating ethanol effects on DA
release in the NAc.

firing rate and marked hyperexcitability accompanies withdrawal (Gallegos et al., 1999), which
is consistent with microdialysis studies demonstrating reductions in DA release during
withdrawal (Diana et al., 1993; Diana, Pistis, Muntoni, & Gessa, 1996). Dr. Steffensen’s lab
reported in 2000 that NAc MSNs were inhibited by physiologically-relevant doses of ethanol and
that ethanol inhibition of NMDA responses in these neurons, as well as VTA and hippocampal
neurons, involves presynaptic GABABRs (Steffensen et al., 2000), which is of particular
relevance to this study. The main question being addressed in this study is: Does ethanol act in
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the VTA to reduce DA neural firing or at DA terminals in the NAc to reduce DA release, or
both? The study is organized around three specific aims and hypotheses.
Our proposed studies constituted a focused investigation into the role of VTA GABA
neuron projections to the NAc, and in particular GABAA and GABABRs, in mediating acute
ethanol effects on DA release in the core under naïve conditions. All the experiments described
in this study involved FSCV measurements (single pulse, multiple pulse, paired-pulse, etc…) of
DA release in the NAc of C57BL/6 mice in vivo and ex vivo following acute ethanol exposure.

Specific Aim 1
To determine the nature of co-dependence of nicotine and ethanol on receptors in the
NAc, we evaluated DA release and uptake with an acute challenge of ethanol and nicotine ex
vivo. We then tested whether nicotinic receptor antagonists block the effects of both nicotine and
ethanol ex vivo. To establish physiological relevance of our findings, we performed
administration of ethanol and nicotine in vivo. We hypothesized that nicotine and ethanol would
produce co-dependence in the NAc as they would both mediate inhibition of DA release in the
NAc through a common receptor binding site.

Specific Aim 2
To determine the effects of acute ethanol on DA release, we evaluated the effects of acute
ethanol (20-160 mM) on peak DA release and uptake in the striatal slice preparation of naïve
C57BL/6 mice. To establish the physiological relevancy of ethanol effects on DA release, we
evaluated the effects of acute ethanol (1-4 g/kg) on peak DA release and uptake in the NAc core
in vivo on C57BL/6 mice. To determine the role of GABA receptors on DA terminals, we
evaluated the GABA and GLU pharmacology of DA release as well as the pharmacology of
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acute ethanol (20-160 mM) inhibition of DA release and uptake in the NAc. We hypothesized
that acute ethanol would inhibit DA release in the NAc core via activation of GABAA or
GABABRs on DA terminals.

Specific Aim 3
To determine the effect on DA release of the isoflavone baicalein on acute ethanol
exposure, we evaluated the effects of baicalein ex vivo (50 μM) and in vivo (1 mg/kg) on peak
DA release of naïve C57BL/6 mice. We hypothesized that acute ethanol inhibition of DA
release in the NAc would be attenuated by the isoflavone baicalein.

Outcomes
In this study, we demonstrate that specific α6*-nAChR antagonist α-conotoxins
effectively block inhibition of evoked DA release caused by both nicotine and ethanol, indicating
that both drugs of abuse have actions on similar targets in the NAc. Additionally, we show that
the α6-subunit is functionally operational in the NAc core, but not the NAc shell, for modulating
evoked DA release.
Another aspect of this study provides important new insights into the role of GABA
receptors regulating DA terminals in the NAc in alcohol reward associated with acute exposure
and provides important new insights into the contributory role of VTA GABA neurons in
regulating DA neurotransmission and ethanol effects on this system. Results from this study
provide a preclinical pharmacologic rationale for considering drugs that act selectively on
GABAAR and/or GABABR subtypes as putative therapeutic agents for the treatment of alcohol
abuse and dependence.
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In correlation to GABA modulation of DA release in the NAc, we tested baicalein in
combination with acute exposure to ethanol and found that DA levels in the NAc will slightly
increase with baicalein administration and that baicalein will attenuate the ethanol inhibition of
DA release and help achieve a homeostatic level, possibly leading to counteracting the addictive
processes of ethanol.
The main objective of this study was to elucidate the mechanism of action of ethanol
inhibition of DA release at terminals in the NAc. We demonstrate that DA release in the NAc is
inhibited by physiologically-relevant concentrations of ethanol and that GABA receptors and
nAChRs are implicated in ethanol inhibition of DA release.
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CHAPTER 2: Materials and Methods
Animal Subjects and Surgical Procedure
The care and use of mice and experimental protocols were approved by the Institutional
Animal Care and Use Committee (IACUC) of Brigham Young University which met or
exceeded NIH guidelines. Three strains of adult mice (PND 30-120) were used in this study:
GABAA δ-subunit knock-out (δ-/-), CD-1 GAD GFP (CD-1), and C57/BL6, with the C57/BL6
mice used as wild-type (WT) controls for all studies involving δ-/- mice. δ-/- mice used were
backcrossed extensively into the C57/BL6 background (Mihalek et al., 2001). Mice in the δ-/colony were genotyped with PCR of ear punches for validation of null mutant genotype (i.e. δ-/-)
for experimentation. Once weaned at PND 21, all mice were housed in groups of four/cage and
placed on a reverse light/dark cycle with lights ON from 8 PM to 8 AM. For DA FSCV
recordings in vivo, mice were anesthetized using isoflurane (MWI Veterinary Supply, Boise, ID)
and placed in a stereotaxic apparatus. Anesthesia levels were maintained at 1 % throughout the
experiments. Body temperature was maintained at 37.4 ± 0.4º C by a feedback regulated heating
pad. With the skull exposed, holes were drilled for placement of stimulating and recording
electrodes.

Preparation of Brain Slices
Horizontal brain slices were obtained as previously described (Steffensen et al., 2008).
Briefly, mice were anesthetized with Ketamine (60 mg/kg), decapitated, and brains were quickly
dissected and sectioned into 400 µm thick horizontal slices in ice-cold artificial cerebrospinal
fluid (ACSF), bubbled with 95 % O2 / 5 % CO2. The cutting solution consisted of (in mM): 220
Sucrose, 3 KCl, 1.25 NaH2PO4, 25 NaH2CO3, 12 MgSO4, 10 Glucose, and 0.2 CaCl2. Slices
were immediately placed into an incubation chamber containing normal ACSF bubbled with 95
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% O2 / 5 % CO2 at 34-35° consisting of (in mM): 124 NaCl, 2 KCl, 1.25 NaH2PO4, 24 NaHCO3,
12 glucose, 1.2 MgSO4, 2 CaCl2, pH 7.3. Slices were incubated for at least 30 minutes prior to
being transferred to a recording chamber. Once transferred to a recording chamber with
continuous normal ACSF flow (2.0 ml/min), the temperature was maintained at 36 °C
throughout the experiment. Slices were allowed to stabilize for an additional 15 min before
recordings were made. The striatum was visualized with Nikon Diaphot (Nikon, Tokyo, Japan)
inverted microscopes in the transmitted mode and the NAc core and shell were visualized by
microscopic inspection under low magnification at the level of the anterior commissure. A red
light filter was placed in the light path to lower the exposure of the slice to short-wavelength
light.

Carbon Fiber Electrodes, Calibration, and Fast Scan Cyclic Voltammetry
For voltammetry recordings both in vivo and ex vivo, a 7.0 µm diameter carbon fiber was
inserted into borosilicate capillary tubing (1.0 mm i.d.; A-M Systems, Sequim, WA) under
negative pressure and subsequently pulled on a vertical pipette puller (Narishige, East Meadow,
NY). The carbon fiber electrode (CFE) was then cut under microscopic control with 200 µm of
bare fiber protruding from the end of the glass micropipette. The CFE was back-filled with 3 M
KCl. The CFEs were regularly calibrated with a known concentration of DA. With the CFE
immersed in the solution of ACSF, we superfused a known concentration of DA at a high flow
rate (5 mL/min) past the electrode and observe the maximum nA signal produced by DA.
Dopamine calibrations were averaged in order to convert a nA signal of DA to µM concentration
of DA.
For ex vivo voltammetry recordings, the CFE was positioned in the NAc. Dopamine
release was evoked by a 4.0 msec, ten-pulse electrical stimulation (monophasic, 350 µA) from a
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bipolar stimulating electrode (Plastics One, Roanoke, VA) placed 100-200 µm from the CFE.
The electrode potential was linearly scanned in voltage-clamp mode as a triangular waveform
from -0.4 to 1.3 V and back to -0.4 V vs Ag/AgCl using a scan rate of 400 V/s. Cyclic
voltammograms were recorded at the CFE every 50 msec (i.e. 20 Hz) by means of a ChemClamp
voltage-clamp amplifier (Dagan Corporation, Minneapolis, MN). Voltammetry recordings were
performed and analyzed using LabVIEW (National Instruments, Austin, TX)-based customized
software. Stimulations were performed periodically every 2 min both in vivo and ex vivo.
Dopamine levels were monitored for a stabilization period typically lasting 1 hr. Once the
stimulated DA response produced stable kinetics, baseline measurements were taken.
For in vivo recordings, mice were anesthetized with isoflurane and placed in a stereotaxic
apparatus (David Kopf Instruments, Tejunga, CA). Bipolar, coated stainless steel electrodes
were stereotaxically implanted into the medial forebrain bundle (MFB; −1.3 P, +1.0 L, 5.0-5.3
V), and a capillary glass-based CFE in the NAc core (+1.3 A, +0.9 L, −3.8-4.5 V). The MFB
was stimulated with 60 biphasic pulses at 60 Hz (4.0 msec pulse width). Stimulation and
recording electrodes were oriented by fine control to optimize the release of DA at 2.0 mA
stimulation intensity. Subsequently, the current was adjusted to that stimulus level which evoked
DA release at 50 % of the maximum DA current level.

Drug Preparation and Administration
For ex vivo experiments, (+/-)-2-amino-5-phosphonovaleric acid (Abcam), bicuculline
(Sigma-Aldrich), chlordiazepoxide (Sigma-Aldrich), muscimol (Sigma-Aldrich), Ro15-4513
(Sigma-Aldrich), picrotoxin (Sigma-Aldrich), CGP55845 hydrochloride (Abcam), baclofen
(Sigma-Aldrich), SKF97541 (Abcam), (1,2,5,6-Tetrahydropyridin-4-yl)methylphosphinic acid
(Tocris), 5α-Pregnan-3α-ol-20-one (Sigma-Aldrich), 5-Andtrosten-3β-ol-17-one sulfate (Sigma19

Aldrich), pentobarbital (Sigma-Aldrich), (4α,5α,17β)-3,17-dihydroxy-4,5-epxoyandrost-2-ene-2carbonitrile (Sigma-Aldrich), 4,5,6,7-Tetrahydroisoxazolo[5,4-c]pyridin-3-ol hydrochloride
(Tocris), (-)-Nicotine hydrogen tartrate salt (Sigma Aldrich), baicalin hydrate (Sigma Aldrich),
baicalein (Caymen Chemicals), dihydro-beta-erythroidine hydrobromide (DHβE, Tocris),
methyllycaconitine (MLA, Sigma Aldrich), α-CtxMII (University of Utah) and α-CtxMII [H9A;
L15A] synthesized as previously described (McIntosh et al., 2004), were dissolved in stock
solutions and then diluted into ACSF for superfusion onto brain slices at a given molar
concentration. For baicalein, we utilized propylene glycol as a solvent.
For in vivo experiments, mecamylamine (MEC, Sigma Aldrich), baicalein [in 3 %
dimethyl sulfoxide (DMSO)], and Ro15-4513 were dissolved in physiological saline solution and
administered intraperitoneally (IP) 30 min prior to ethanol administration. Nicotine was
dissolved in physiological saline solution and administered intravenously. Ethanol was
administered IP at 16 % w/v in physiological saline solution.

Cerebral Lesion and Verification of Electrode Placement
Following the in vivo experimentation, a current of 2.5 mA was applied through the CFE
for 5 seconds with a 5 second interval at both polarities. This current induced an electrolytic
lesion in the tissue. The perfused brains were then sliced coronally at 500 µm with a vibratome
and visualized under light microscope to confirm placement of the electrode in either the NAc
shell or core.

Immunohistochemistry
In order to visualize evidence of ρ1-subunits in the NAc, CD-1 mice were perfused as
previously described (Jang et al., 2014). Mice brains were removed under pentobarbital
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anesthesia (80 mg/kg, IP), post-fixed with 4 % paraformaldehyde, cryoprotected in 30 %
sucrose, and cryosectioned into 30 µm slices. The sections were incubated in blocking buffer
containing 4 % normal goat serum and 0.1 % bovine serum albumin at room temperature for 1
hour. The sections were incubated with primary antibody for rabbit anti-GABRR1 (1:200;
Biorbyt, San Francisco, CA) at 4º C overnight. The sections were then processed with secondary
antibodies, goat anti-rabbit Alexa Fluor 594 (red; 1:250; Invitrogen, OR) at room temperature for
2 hours. Tissue sections were imaged with a 40X objective using a confocal fluorescent imaging
system (Olympus FluoView FV1000, PA).

Statistical Analyses
The results for control and drug treatment groups were derived from calculations
performed on voltammetry current vs time plots. Peak amplitude was determined by a median
filter peak detection algorithm in LabVIEW. Three successive DA peak responses were
averaged for control and drug conditions within each experiment. The means were then grandaveraged across animals. Values were expressed as means ± SEM for cumulated data. Betweensubject group comparisons were analyzed via either t-tests or one-way ANOVAs. Withinsubject frequency responses were analyzed with a two-way repeated measures ANOVA, with
frequency and drug as the within subject comparisons. Within-subjects comparisons were
evaluated via one-way ANOVA and between-subject comparisons were evaluated via one-way
ANOVA with Tukey post-hoc analysis where pertinent. For the comparison between δ-/- and
WT mice, a two-way ANOVA was performed with genotype as the between-subject factor and
ethanol concentration as the within-subject factor. The criterion of significance was set at
p<0.05 (*), p<0.01 (**), and p<0.001 (***). All statistics were calculated with IBM SPSS
Statistics 21 (Armonk, New York).
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CHAPTER 3: Results
Nicotine Dose-Response, Frequency-Response and Pharmacology in the Shell Region of the
Nucleus Accumbens
Using FSCV, we evaluated the effects of nicotine (0.01 – 10 µM) on evoked DA release
in the NAc shell. Nicotine significantly decreased the peak amplitude of the DA signal with an
IC50 of approximately 0.1 µM (Fig. 2A, B; 0.01 µM: p=0.39, n=4; 0.1 µM: p=0.001, n=4; 1.0
µM: p=0.001, n=4; 10.0 µM: p<0.0001, n=7). We evaluated the frequency dependency for
nicotine effects on DA release in the NAc shell. We applied stimulation trains (10 pulses) at
varying frequencies ranging from 10 - 200 Hz and compared the response produced by multiple

Figure 2: Pharmacology of Nicotine Inhibition of Evoked DA Release in the Shell of the NAc Ex Vivo. (A)
Superfusion of nicotine (10 µM) reduced DA release in this representative recording from the NAc shell
slice preparation. Inset shows superimposed DA signals obtained before and after superfusion of nicotine.
Calibration bars are nA and seconds. (B) Nicotine significantly reduced DA release with an IC50 of 0.1 µM.
(C) Nicotine significantly reduced phasic DA release in the NAc shell across all frequencies tested. (D)
Pharmacology of nicotine inhibition of DA release in the shell. While the α6*-nAChR antagonist α-CtxMII
had no effect on nicotine inhibition of DA release at 0.1 µM (the IC50 level), the α4β2 antagonist dihydrobeta-erythroidine hydrobromide (DHβE) significantly reduced nicotine inhibition of DA release in the NAc
shell. Values in parentheses represent n values.
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pulses to that obtained by a single pulse. The frequency response followed an inverted-U
relationship, with the maximum release occurring at 40 Hz stimulation in the NAc shell (Fig.
2C). Nicotine significantly decreased the amplitude of the DA signal across all frequencies
tested. Two-way repeated measures ANOVA revealed a main effect of frequency for the
amplitude of the DA signal (F5,20=2.897, p=0.04), and nicotine (F1,4=16.367, p=0.016). Next we
evaluated the effects of various nAChR antagonists on evoked DA release in the NAc shell. We
analyzed evoked DA release in the presence of nicotine with the selective α6* antagonist αCtxMII (100 nM) and also the partially selective α4β2* antagonist DHβE (50 µM) Superfusion
of α-CtxMII did not block the inhibition caused by 0.1 µM nicotine in the NAc shell whereas
DHβE did (Fig. 2D). α-CtxMII did not significantly affect the DA signal (F1,7=0.090, p=0.773).
However, superfusion of DHβE significantly inhibited the DA signal about 40% from baseline.
There was no statistical significance between α-CtxMII exposed nicotine and control nicotine
(p>0.05). However, one-way ANOVA comparing effects of DHβE + nicotine to nicotine alone
on evoked DA in the NAc shell revealed a significant attenuation in nicotine effects on NAc
shell DA transmission (F(1,6)=35.376, p=0.001). Additionally, DHβE blockade of nicotine
induced DA reductions was significantly increased when compared to α-CtxMII experiments
(F1,7=27.790, p=0.0012).

Nicotine Dose-Response, Frequency-Response and Pharmacology in the Core Region of the
Nucleus Accumbens
Using FSCV, we evaluated the effects of nicotine (0.01 – 10 µM) on evoked DA release
in the NAc core. Nicotine significantly decreased the peak amplitude of the DA signal with an
IC50 of approximately 0.1 µM (Fig. 3A, B; 0.01 µM: p=0.269, n=4; 0.1 µM: p=0.006, n=4; 1.0
µM: p=0.001, n=4; 10.0 µM: p=0.002, n=7). We noted varying results at higher concentrations
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Figure 3: Pharmacology of Nicotine Inhibition of Evoked DA Release in the Core of the NAc Ex
Vivo. (A) Superfusion of nicotine (10 µM) reduced DA release in this representative recording
from the NAc core slice preparation. Inset shows superimposed DA signals obtained before and
after superfusion of nicotine. Calibration bars are nA and seconds. (B) Nicotine significantly
reduced DA release with an IC50 of 0.1 µM. (C) Nicotine significantly reduced phasic DA release
in the NAc core across frequencies. (D) Pharmacology of nicotine inhibition of DA release in the
core. The α6*-nAChR antagonist α-conotoxins α-CtxMII and α-CtxMII [H9A; L15A] significantly
reduced nicotine inhibition of DA release in the NAc core. Values in parentheses represent n
values.

of nicotine (10 µM) in the NAc shell (Fig. 2B) vs the NAc core (Fig.3B). Specifically, there was
a significant difference between the shell and the core at the 10 µM nicotine concentration
(F1,12=35.765, p<0.0001). The frequency dependency for nicotine effects on DA release in the
NAc core (Fig. 3C) was similar to the shell; however, the maximum release occurred at 20 Hz
rather than 40 Hz. Nicotine significantly decreased the amplitude of the DA signal across all
frequencies tested. Two-way repeated measures ANOVA revealed a main effect of frequency
for the amplitude of the DA signal (F5,15=16.632, p=0.0001), and nicotine (F1,3=592.034,
p=0.0002). We analyzed the effects of the α6 antagonist α-conotoxins α-CtxMII (100 nM) and
α-CtxMII [H9A; L15A] on nicotine inhibition of evoked DA release in the NAc core. We
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utilized the more specific α-CtxMII [H9A; L15A] to compare with α-CtxMII. However, as αCtxMII [H9A; L15A] is less potent (McIntosh et al., 2004), a higher concentration (500 nM)
was utilized. Superfusion of α-CtxMII significantly inhibited the DA signal about 30% from
baseline while the more specific α6* antagonist α-CtxMII [H9A; L15A] only slightly inhibited
the DA signal 8% from baseline. Both of the α-conotoxins blocked the inhibition caused by 0.1
µM nicotine in the NAc core (Fig. 3D). One-way ANOVA comparing nicotine and MII +
nicotine revealed significance (F1,8=48.971, p=0.0001). Given that α-CtxMII in the NAc core
completely attenuated the inhibition of nicotine, we determined not to perform any additional
experiments with other nAChR antagonists (as we did in the NAc shell) as nicotine was
apparently not acting by any other nAChR subunit in the NAc core. One-way ANOVA
comparing nicotine and MII [H9A; L15A] + nicotine revealed significant reductions in nicotine
effects in MII pretreated slices (F1,8=8.775, p=0.0181).

Ethanol Inhibition of Dopamine Release in the Nucleus Accumbens: Role of α6*-nAChRs
As nicotine inhibition of evoked DA release in the core was blocked by the α6 antagonist
α-CtxMII (100 nM), and we have previously demonstrated that ethanol similarly decreases
evoked DA release in the core (Yorgason et al., 2013), we evaluated the effects of ethanol (20 –
160 mM) on DA release, as well as the effects of α-CtxMII (100 nM) on ethanol inhibition of
DA release in the NAc core. From our previous experimentation, we have noted no disparities of
the effects of ethanol in the NAc shell or core as we have with nicotine. Ethanol significantly
decreased the peak amplitude of the DA signal with an IC50 of approximately 80 mM (Fig. 4A,
B; 20 mM: p=0.001, n=11; 40 mM: p=0.001, n=11; 80 mM: p=0.0002, n=11; 160 mM:
p<0.0001, n=10). Ethanol significantly decreased the amplitude of the DA signal across all
frequencies tested with the exception of single pulse stimulation (Fig. 4C). This confirms the
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Figure 4: Nicotinic Receptor Pharmacology of Ethanol Inhibition of Evoked DA Release in the Core of
the NAc Ex Vivo. (A) Superfusion of ethanol (80 mM) reduced DA release in this representative
recording from the NAc core slice preparation. Inset shows superimposed DA signals obtained before
and after superfusion of ethanol. Calibration bars are nA and seconds. (B) Ethanol significantly reduced
DA release with an IC50 of 80 mM. (C) Superfusion of ethanol significantly reduced phasic DA release
across frequencies 10 - 80 Hz. (D) Pharmacology of ethanol inhibition of DA release in the core. While
the α7 nAChR antagonist MLA did not alter ethanol inhibition of DA release, the α6*-nAChR antagonist
α-CtxMII [H9A; L15A] significantly reduced ethanol inhibition of DA release in the NAc core. Values
in parentheses represent n values.

frequency dependent nature of ethanol in the NAc reported previously (Yorgason et al., 2013).
A two-way Repeated Measures ANOVA revealed a main effect of frequency for the amplitude
of the DA signal (F4,32=25.703, p<0.0001), ethanol (F1,8=6.744, p=0.032), and interaction of
frequency by ethanol (F1,8=4.427, p=0.006). We analyzed evoked DA release in the presence of
ethanol with the specific α7 and α6 nAChR antagonists methylylcaconitine (MLA; 100 nM) and
α-CtxMII [H9A; L15A] (500 nM), respectively. MLA did not alter ethanol inhibition of evoked
DA release in the core at 80 mM ethanol (Fig. 4D; F1,20=0.478, p=0.497). However, superfusion
of the specific α6*-nAChR antagonist α-CtxMII revealed a significant effect of α-CtxMII [H9A;
L15A] on ethanol inhibition of evoked DA release in the NAc (Fig. 4D; F1,30=4.296, p=0.047).
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Figure 5: Pharmacology of Nicotine Effects of Evoked DA Release in the Shell and Core of the NAc In
Vivo. (A) Intravenous administration of nicotine (0.5 mg/kg) reduced DA release in this representative
recording from the NAc shell in vivo. Inset shows superimposed DA signals obtained before and after
injection of nicotine. Calibration bars are nA and seconds. (B) Intravenous administration of nicotine
significantly reduced DA release in the NAc core. (C) Summary of nicotine effects on DA release in
vivo. At similar doses of nicotine, the release of DA in the NAc shell and core vary significantly, with
the core demonstrating significant decrease from baseline and from the shell at both dose levels. (D)
Representative coronal brain slice through the NAc. Solid lines represent electrode placements in the
NAc core. Dashed lines represent electrode placements in the NAc shell. (aca = anterior commissure,
LAcbSh = lateral accumbens shell, AcbSh = Accumbens shell.) Values in parentheses represent n
values.

Effects of Nicotine In Vivo In Both the Shell and Core of the Nucleus Accumbens
Utilizing FSCV, we evaluated the effects of i.v. nicotine (0.15 – 0.5 mg/kg) on evoked
DA release in the NAc shell and core in vivo. Nicotine had a slightly excitatory effect in the
NAc shell (Fig. 5A, C), although it did not prove statistically significant via one-way ANOVA at
0.15 mg/kg (F(1,7)=1.508, p=0.265) or 0.5 mg/kg (F1,13=3.008, p=0.108). However, nicotine had
an inhibitory effect on evoked DA release in the NAc core at both 0.15 mg/kg (F(1,9)=10.435,
27

p<0.012) and 0.5 mg/kg (Fig. 5B, C; F1,15=27.766,
p<0.0001). Although an IC50 is statistically visualized
at 0.15 mg/kg, the signals were more inconsistent at
that dose than at 0.5 mg/kg. Thus, we utilized 0.5
mg/kg nicotine as our IC50 dose. As observed with the
ex vivo experimentation, there was a significant
difference between the response of the NAc shell and
core with nicotine administration (Fig. 5C). One-way
ANOVA revealed significance of 0.15 mg/kg core vs
shell (F1,8=8.874, p=0.021) and 0.5 mg/kg core vs shell
(F1,14=25.448, p=0.0002). Electrode placements were
verified by microscopically visualizing the lesions in
coronal slices induced by high current at the tip of the
CFE (Fig. 5D).

Role of nAChRs In Ethanol Inhibition of Dopamine
Release In Vivo
Typically, acute ethanol administration (2 g/kg)
reduces the DA signal approximately 50% (Fig. 6A) in
vivo. It has previously been shown that the non-specific
nAChR antagonist mecamylamine [(MEC); (Peng et
al., 2013)] reduces ethanol consumption and blocks
ethanol-induced DA release in the NAc (Blomqvist,
Engel, Nissbrandt, & Soderpalm, 1993; Hendrickson et
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Figure 6. Nicotinic Receptor
Pharmacology of Ethanol Inhibition of
Evoked DA Release in the Core of the
NAc In Vivo. (A) Representative time
course of DA release in the NAc core in
an anesthetized mouse demonstrating
inhibition produced by i.p. administration
of ethanol (2 g/kg). Inset shows
superimposed DA signals obtained before
and 30 min after injection of ethanol.
Calibration bars are nA and seconds. (B)
Representative time course of DA release
in the NAc demonstrating the blocking
effect of i.p. injection of MEC (1 mg/kg)
on the inhibition typically produced by the
administration of ethanol. Inset
demonstrates representative nA recordings
of DA release in control, MEC, and
ethanol conditions. Calibration bars are
nA and seconds. (C) Pharmacology of
ethanol inhibition of DA release in vivo.
Ethanol inhibits DA release at an IC50 of
2.0 g/kg. With the administration of
MEC, ethanol has significantly less effect
on DA release (p=0.002). All values of
MEC are normalized to control
conditions. Values in parentheses
represent n values.

al., 2013). In order to understand how nAChRs contribute to ethanol’s inhibitory effects on DA
in the NAc, we evaluated the effects of MEC on evoked DA signals in anesthetized mice.
Mecamylamine did not alter the DA signal on its own, consistent with our ex vivo studies (data
not shown). However, MEC (1 mg/kg, i.p.) effectively blocked the inhibitory effects of ethanol
in the NAc (Fig. 6B). Normalizing data to control values, MEC + ethanol demonstrated a
statistical significance from ethanol alone (Fig. 6C; F1,24=12.279, p=0.002).

Effects of NMDA Antagonist APV on Dopamine
Release in the Nucleus Accumbens Ex Vivo
Whenever there is a change in neuron firing
intensity or quantal neurotransmitter release, it is
important to first determine whether changes are due to
NMDA related long-term potentiation (LTP). As we
have previously demonstrated that ethanol significantly
reduces phasic DA release (Schilaty et al., 2014;
Yorgason et al., 2013), we tested the effects of the
NMDA antagonist D- 2-amino-5-phosphonovaleric
acid (APV) on DA release in the NAc. The slices were
pre-treated with APV (50 µM) for 1 hour prior to
experimentation. In the presence of APV, phasic DA
release was inhibited by superfusion of 80 mM ethanol
(Fig. 7A), the IC50 level of ethanol on phasic DA
release (Schilaty et al., 2014; Yorgason et al., 2013).

Figure 7: Effects of APV on Phasic DA
Release Ex Vivo. (A) Slices were
presoaked in APV, and APV was present
throughout the experiment. This is a
representative example that demonstrates
that APV failed to attenuate ethanol
inhibition of phasic dopamine release at
the IC50 for ethanol (80 mM). Calibration
bars are nA and seconds. (B)
Pharmacology of ethanol inhibition of DA
release in the NAc. APV has no statistical
effect on altering ethanol’s depression of
DA release. Values in parentheses
represent n values.

Two-way ANOVA of control vs control ethanol revealed a main effect of ethanol (F1,33=33.6,
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p<0.0001) but no significant effect of APV (p>0.05) and no interactions between APV and
ethanol (Fig. 7B; p>0.05).

Effects of GABAA Typical Agonists and Antagonists on
Dopamine Release in the Nucleus Accumbens Ex Vivo
To determine the role of GABA in ethanol
inhibition of DA release in the NAc, and the
pharmacological characteristics of the hypothesized
GABAAR present in the NAc that is modulating the
release of DA, we evaluated the effects of superfusion of
GABA and select GABAAR agonists and antagonists.
Superfusion of GABA (100 nM – 10 mM) demonstrated
a sensitivity at 10 µM via one-way ANOVA (Fig. 8A;
F1,17=28.85, p<0.0001) and at very high concentration
levels via one-way ANOVA [1 – 10 mM; at 1 mM (Fig.
Figure 8: Effects of GABAA Agonists
and Antagonists on Phasic DA Release
Ex Vivo. (A) Concentration response
curve of exogenous GABA (100 nM –
10 mM). GABA had attenuating effects
on DA release at 10 μM and at high
concentrations (3 – 10 mM). (B)
Concentration response curve of
muscimol (1 – 350 μM). Muscimol did
not significantly affect DA release until
extremely high concentration (350 μM).
(C) GABAA antagonist pharmacology
of evoked DA release in the NAc.
Bicuculline (10 μM) did not significantly
alter the effects of ethanol on evoked
DA release. Picrotoxin (10 μM) did not
significantly alter the effects of ethanol
on evoked DA release. Ro15-4513 (10
μM) significantly attenuated the effects
of ethanol on evoked DA release.
Values in parentheses represent n values.

8A; F1,23=12.302, p=0.002)]. Superfusion of the potent,
selective GABAA agonist, muscimol (1 – 350 µM), did
not significantly affect phasic DA release at 1 – 100 µM,
but significantly reduced phasic DA release at the high
concentration (350 µM; Fig. 8B; F1,10=132.34,
p<0.0001). We tested the effects of select GABA
antagonists on phasic DA release and ethanol inhibition
of phasic DA release. The chloride channel GABA
antagonist picrotoxin demonstrated marginal
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effectiveness in attenuating ethanol inhibition of DA release at 10 µM , a dose typically used by
us and others to block GABA inhibition of mesolimbic neuronal activity, however the results
were not statistically significant (Fig. 8C; F1,13=2.906, p=0.112). The GABAAR antagonist,
bicuculline (10 µM), a dose typically used by us and
others to block GABAAR-mediated inhibition, had no
effect on its own, and was completely ineffective at
blocking ethanol inhibition of DA release (Fig. 8C;
F1,16=0.174, p=0.682).

Effects of Chlordiazepoxide and Pentobarbital on
Dopamine Release in the Nucleus Accumbens Ex Vivo
Benzodiazepines and barbiturates are well
known drugs that act as potent GABAA positive
allosteric modulators, potentiating the effects of GABA
at the GABAAR (Carter, Kozuska, & Dunn, 2010).
Additionally, the binding sites of barbiturates and
benzodiazepines are distinct and separate from one
another and from GABA. Superfusion of the
benzodiazepine chlordiazepoxide (CDX; 30 µM), a dose
used by us and others to enhance GABA inhibition
(Kasparov et al., 2001), did not significantly affect
phasic DA release as seen with 80 mM ethanol
superfusion (Fig. 9A, C; F1,13=1.269, p=0.280).
Superfusion of the barbiturate pentobarbital (100 µM)
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Figure 9: Effects of Benzodiazepines and
Barbiturates on DA Release Ex Vivo.
(A) This is a representative example that
demonstrates no effect by CDX (30 μM)
superfusion followed by superfusion of
ethanol (80 mM). Inset demonstrates
current by time plot. Calibration bars are
nA and seconds. (B) This is a
representative example that demonstrates
no effect by pentobarbital (100 μM)
superfusion followed by superfusion of
ethanol (80 mM). Inset demonstrates
current by time plot. Calibration bars are
nA and seconds. (C) Both pentobarbital
(100 μM) and CDX (30 μM) failed to
significantly attenuate the effects of
ethanol (80 mM). Values in parentheses
represent n values.

had no effect on DA release and did not alter the
effects of ethanol (Fig. 9B, C; F1,13=0.043,
p=0.838).

Effects of GABAB Agonists and Antagonists on
Dopamine Release in the Nucleus Accumbens Ex
Vivo
Due to the lack of effects of typical GABAA
agonists to mimic the effects of the IC50 of ethanol,
as well as the lack of typical GABA antagonists to
affect ethanol inhibition of phasic DA release, we
evaluated the effects of select GABAB receptor
agonists and antagonists. Superfusion of the
GABAB agonist baclofen (0.001 – 2 mM) did not
significantly affect phasic DA release until 100 µM
(Fig. 10A; F1,6=10.555, p=0.017), a dose that is
Figure 10: Effects of GABAB Agonists and
Antagonists on Phasic DA Release Ex Vivo.
(A) Concentration response curve of the
GABAB agonist baclofen (1 μM – 2 mM).
Baclofen did not affect DA release until
uncharacteristically high concentrations of
baclofen (100 μM). (B) This is a
representative example that demonstrates
increase of DA via GABAB antagonist
CGP55845 (10 μM). CGP55845 significantly
raises DA release and significantly attenuates
ethanol inhibition of DA release. Inset
demonstrates current by time plot.
Calibration bars are nA and seconds. (C) All
three doses of CGP55845 (5 – 50 μM)
demonstrate significant increases of DA
release. (D) CGP55845 (10 μM)
significantly attenuates the ethanol inhibition
of DA release. Values in parentheses
represent n values.

100X higher than the typical IC50 effect of baclofen
on neuronal activity in the mesolimbic neurons.
Interestingly, the potent and selective antagonist
CGP55845 (5 – 50 µM) remarkably raised DA
release on its own and significantly attenuated
ethanol inhibition of phasic DA release (Fig. 10B,
C; F1,15=7.653, p=0.014). As the GABAB antagonist
was effective in altering the response of terminal
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evoked DA release but baclofen was not effective under normal concentrations, we tested the
effects of SKF97541, a GABAB agonist that is 10X more potent than baclofen. SKF97541 (10
µM) did not significantly affect phasic DA release in the NAc (data not shown; F1,11=0.460,
p=0.512), suggesting that CGP55845 may be acting through non-GABAB dependent
mechanisms to enhance DA release and attenuate ethanol’s effects.

Effects of GABAA δ-subunit Agonists and
Antagonists and GABAA δ-subunit Knock Out
Mice on Dopamine Release in the Nucleus
Accumbens Ex Vivo
Given that the typical GABAA agonists
and antagonists were ineffective in altering
evoked DA release, and that there were mixed
results with GABAB agonists and antagonists, we
considered the involvement of atypical GABAAR
subunits. Superfusion of the δ-subunit selective
GABAA agonist 4,5,6,7-Tetrahydroisoxazolo[5,4c]pyridin-3-ol hydrochloride (THIP; 10 nM – 10
µM) had no effect on phasic DA release (Fig.
11A). Superfusion of the δ-subunit selective
GABAA antagonist Ro15-4513 (10 µM) had no
effect on phasic DA release, but significantly
reduced ethanol inhibition of phasic DA release
(Fig. 8C; F1,15=7.618, p=0.015). Subsequently,

Figure 11. Effects on GABA Delta-subunit
Pharmacology Ex Vivo and Delta Knock-out
Mouse with Acute Ethanol. (A) Concentration
response curve of the α4β3δ selective agonist
THIP (10 nM – 10 μM). THIP did not
demonstrate attenuating effects on DA release in
the customary concentration range. (B) δ-/- mice
demonstrate insensitivity to ethanol (20 – 160
mM) compared to WT mice. The tested
concentrations of ethanol in δ-/- mice were
actually excitatory on DA release. Significance
values were determined by one-way ANOVA
between strains at their respective ethanol
concentrations.

we utilized δ-/- mice to evaluate their dose-response sensitivity to ethanol ex vivo at the same
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concentration levels (20 mM – 160 mM) as WT
mice. Compared to WT mice, the δ-/- mice
demonstrated enhanced phasic DA release with
exposure to all concentrations of ethanol (Fig.
11B). Two-way ANOVA revealed significance
of strain (F1,59=62.41, p<0.0001), concentration
(F1,59=8.09, p=0.0006), and strain by
concentration (F1,59=4.11, p=0.0163).

Effects of Neurosteroids on Dopamine Release
in the Nucleus Accumbens Ex Vivo
Superfusion of allopregnanolone
(ALLO; 20 µM), a potent GABAAR positive
allosteric neurosteroid modulator, did not alter
DA release on its own but slightly attenuated

Figure 12. Effects of Neurosteroids on Phasic DA
Release Ex Vivo. (A) This is a representative
example that demonstrates the lack of effect by
ALLO (20 μM) superfusion on DA release and a
moderate attenuation of the effects of ethanol (80
mM). Inset demonstrates current by time plot.
Calibration bars are nA and seconds. (B) This is
a representative example that demonstrates the
lack of effect by Trilostane (20 μM) superfusion
alone but a significant attenuation of ethanol
inhibition of DA release (80 mM). Inset
demonstrates current by time plot. Calibration
bars are nA and seconds. (C) This is a
representative example that demonstrates an
excitatory effect of DHEAS (10 μM) superfusion
alone and a significant attenuation of ethanol
inhibition of DA release (80 mM). Inset
demonstrates current by time plot. Calibration
bars are nA and seconds. (D) All three
neurosteroids – ALLO, Trilostane, and DHEAS –
demonstrate significant attenuation of the ethanol
inhibition of DA release in the NAc. Values in
parentheses represent n values.

ethanol inhibition of DA release (Fig. 12A, D;
F1,14 = 6.316, p = 0.025). Superfusion of
(4α,5α,17β)-3,17-dihydroxy-4,5-epxoyandrost2-ene-2-carbonitrile (Trilostane; 20 µM), an
inhibitor of 3β-hydroxysteroid dehydrogenase
(effectively raising endogenous levels of the
neurosteroid dehydroepiandrosterone-sulfate
(DHEAS), produced no significant effects on
DA release on its own, yet significantly
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attenuated the effects of ethanol (Fig. 12B, D; F1,14=6.073, p=0.027). Superfusion of the
GABAAR negative allosteric modulator DHEAS (10 µM) increased DA release and markedly
attenuated the effects of ethanol on DA release (Fig. 12C, D; F1,13=19.416, p=0.001).

Effects of Ro15-4513 on Dopamine Release in the
Nucleus Accumbens In Vivo
To confirm the physiological relevancy of
atypical GABAAR antagonists on ethanol inhibition
of phasic DA release ex vivo, we evaluated the effects
of the δ-subunit selective GABAA antagonist, Ro154513 in vivo. We have previously demonstrated that
ethanol reduces phasic DA release in vivo (Fig. 13A)
with an IC50 of 2.0 g/kg (Schilaty et al., 2014),
similar to what others have shown. Administration of
the Ro15-4513 (1.5 mg/kg, IP), did not affect DA
release (Fig. 13B; F1,10=0.509, p=0.492), but
significantly attenuated ethanol inhibition of phasic
DA release in the NAc in isoflurane-anesthetized
mice compared to ethanol controls (Fig. 13C;
F1,14=12.223, p=0.004).

35

Figure 13. Ro15-4513 Reduces Ethanol
Inhibition of DA Release In Vivo. (A) This
is a representative example that demonstrates
the effect of saline and the ID50 of ethanol (2
g/kg) IP injection. Inset demonstrates current
by time plot. Calibration bars are nA and
seconds. (B) This is a representative
example that demonstrates the effect of
Ro15-4513 (1.5 mg/kg) and ID50 of ethanol
(2 g/kg). Inset demonstrates current by time
plot. Calibration bars are nA and seconds.
(C) Increasing doses of ethanol (1.0 – 4.0
g/kg) lower evoked DA release in vivo.
Administration of Ro15-4513 (IP)
significantly attenuates the ethanol inhibition
of DA release. Values in parentheses
represent n values.

Effects of GABAA ρ-subunit Antagonist TPMPA on Dopamine Release in the Nucleus Accumbens
To confirm evidence of GABAA ρ1-subunit
pharmacology, we tested the ρ1-subunit antagonist,
1,2,5,6-Tetrahydropyridin-4-yl)methylphosphinic
acid (TPMPA). Superfusion of TPMPA (10 µM)
produced a mild (but statistically insignificant)
increase in evoked DA release on its own (Fig.
14A), but significantly attenuated ethanol
inhibition of phasic DA release in the NAc (Fig.
14B; F1,13=17.124, p=0.001).
Figure 14. Effect of ρ1-subunit Antagonist
TPMPA on Phasic DA Release Ex Vivo. (A)
This is a representative example that
demonstrates superfusion of the ρ1 specific
antagonist TPMPA (10 μM) slightly raising DA
release. Superfusion of the IC50 of ethanol (80
mM) was significantly attenuated. In addition,
washing both TPMPA and ethanol from the slice
produced even greater excitation of DA release.
Inset demonstrates current by time plot.
Calibration bars are nA and seconds. (B)
TPMPA significantly attenuates the ethanol
inhibition of DA release. Values in parentheses
represent n values.

Immunohistochemistry of GABAA ρ1-subunit in the
Nucleus Accumbens
To identify the presence of the GABAA ρ1subunits in the NAc, we observed GABRR1
labeled subunits using immunofluorescence.
Images identified the presence of ρ1-subunits (Fig.
15) in the NAc. Labeling of ρ1-subunits was

observed in both GAD-GFP+ and non-GFP+ cell populations (with utilization of FITC filter) in
CD-1 mice. Combined viewing clearly distinguished the ρ1-containing neurons from the GABA
containing neurons.
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Figure 15. Expression of GABAA ρ1-subunit in Nucleus Accumbens of CD-1 Mice. GABA neurons were
revealed by green fluorescence from FITC filter (A) and GABAA ρ1 subunit immunoreactivity was revealed
with red fluorescence in the NAc of CD-1 mice (B). This image shows that most GABAA ρ1-subunits were in
GABA neurons in the NAc (C). The bar indicates a scale of 100 µm. AC = anterior commissure.
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Effects of Baicalein on Dopamine Release in the Nucleus Accumbens Ex Vivo
To verify whether the isoflavone baicalein could
serve as a potential nutraceutical agent for counteracting
the effects of ethanol, we superfused baicalin hydrate (50
μM) prior to the superfusion of ethanol (80 mM).
Baicalin hydrate appeared to significantly attenuate the
inhibitory effects of ethanol on DA release in the NAc ex
vivo (data not shown), however, we discovered that
baicalin hydrate has a redox potential similar to DA and
masked the effects seen by ethanol inhibition. Thus, we
determined to use baicalein (as it does not have a redox
potential similar to DA) dissolved in either DMSO or
propylene glycol. With the ex vivo setup, concentrations
of DMSO (0.1 – 10%) produced significant electrode

Figure 16. Baicalein Prevents Ethanol
Inhibition of DA Release In Vivo. (A)
This graph shows the time course of 2.0
g/kg ethanol effects on a representative
recording of DA release in the NAc. (B)
Baicalein attenuates the typical
inhibitory effect of ethanol on DA
release.

issues in which the DA signal would be lost. Thus, we switched to the solvent propylene glycol.
Unfortunately, at reasonable concentration of propylene glycol (1 – 20%), we were not able to
obtain complete solubility of baicalein for superfusion. Thus, with incomplete solubility of
baicalein (50 µM; and thus inaccurate parameters on concentration), baicalein significantly
attenuated the ethanol inhibition of DA release (Fig. 17A, F1,16=28.010, p<0.001).
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Effects of Baicalein on Dopamine Release in the Nucleus Accumbens In Vivo
As ex vivo did not demonstrate accurate
results based on the insufficiency of solubility of
baicalein in both DMSO and propylene glycol and
the redox potential of the baicalein metabolite
baicalin hydrate, we dissolved baicalein (1 mg/kg)
in DMSO (3 %) and administered it IP 30 minutes
prior to ethanol (2.0 g/kg). Baicalein significantly
attenuated the ethanol inhibition of DA release in
the NAc in vivo (Fig. 16A, B; 17B; F1,8=11.292,
p=0.01).

Figure 17. Baicalein Attenuates Ethanol
Inhibition of DA Release Both Ex Vivo and In
Vivo. (A) This graph demonstrates the
significant attenuation of DA neurotransmission
with 50 µM baicalein and 80 mM ethanol
superfusion against normalized controls. (B)
This graph demonstrates the significant
attenuation of DA neurotransmission with 1
mg/kg baicalein (IP) and 2 g/kg ethanol (IP)
administration against normalized controls.
Numbers in parentheses represent n values.
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CHAPTER 4: Discussion
We demonstrated that evoked DA release is reduced by nicotine application in the NAc
shell and core ex vivo. These inhibitory effects of nicotine were observed across all frequencies
and were blocked by nAChR antagonists. Specifically, in the shell, nicotine’s effects were
blocked by the α4β2* selective antagonist DHβE, but not by the α6 nAChR antagonist α-CtxMII.
In contrast, nicotine modulation of DA signals in the core appears to be more through α6
nAChRs, as α-CtxMII, and the more selective α6 antagonist α-CtxMII [H9A; L15A], blocked
nicotine’s inhibition of evoked DA release. Similar to previous studies, we demonstrated that
ethanol reduces stimulated DA release in the core in a frequency dependent manner, with
greatest inhibition at higher stimulation frequencies. Ethanol’s inhibitory effects were blocked
by α-CtxMII [H9A; L15A], but not MLA, suggesting that ethanol is acting through heteromeric
a6* nAChRs, and not α7 homomeric receptors. We also demonstrated that the non-specific
nAChR antagonist MEC also block’s ethanol’s inhibitory effects on evoked DA release under in
vivo conditions.

Region Dependent Nicotine Modulation of Dopamine Release
Nicotine decreased evoked DA release ex vivo in both the shell and the core of the NAc
with an IC50 of 0.1 µM. Nicotine behaved similarly in the NAc shell and core except for at the
highest concentration of 10 µM, where the NAc core demonstrated significantly less inhibition
of DA release (Fig. 1B, 2B), suggesting that the α6* nAChRs in the NAc core desensitize to high
concentrations of nicotine as compared to nAChRs in the NAc shell. More importantly, this
significant variability in response to the higher concentrations of nicotine in the NAc core vs
NAc shell demonstrates specific differences in nAChRs subunits in the NAc core and the NAc
shell. Nicotine decreased evoked DA release in the core in vivo, but had no significant effect in
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the shell. Although these results do not exactly correspond to our findings ex vivo, it is important
to note that the ex vivo recordings are less influenced by intact circuit responses, but rather the
behavior of stimulation at terminals of the neurons in the NAc. More importantly, the in vivo
results demonstrate and further verify that there exists a significant variability in the nAChRs
present in the NAc shell and core and provide compelling evidence that the ex vivo
pharmacology demonstrated was valid.
Neuronal nicotinic acetylcholine receptors (nAChRs) are ligand-gated cation (primarily
Na+ or Ca2+) channels of a wide variety in the central nervous system (CNS). These channels can
exist in either homomeric or heteromeric form, with the α7 subunit composing the most common
homomeric nAChR in the CNS, and pentameric mixture of alpha (α2- α10) and beta (β2-β4)
subunits, with α4β2*-nAChRs as the most common heteromeric CNS receptor (Taylor, Burman,
et al., 2013). Although nAChRs are of a wide variety in the VTA (Wooltorton, Pidoplichko,
Broide, & Dani, 2003), heteromeric α6*-nAChRs are highly expressed in the mesolimbic DA
system (Champtiaux et al., 2003; K. Yang et al., 2011; K. C. Yang, Jin, & Wu, 2009), and α6 is
the primary α subunit that plays a prominent role in DA release (Quik, Perez, & Grady, 2011),
and they are predominantly expressed in catecholaminergic systems (Brunzell, 2012). α6*nAChR subunits are functional in recombinant systems when paired with β subunits or hybrids
of α subunits. In fact, expression of the α6 nAChR subunit is 16-fold higher than other subunit
mRNAs in the VTA (K. Yang et al., 2009), and they have been implicated in DA transmission
and nicotine dependence (Brunzell, 2012; Drenan et al., 2010; Drenan et al., 2008; Exley et al.,
2008; Gotti et al., 2010; Jackson, McIntosh, Brunzell, Sanjakdar, & Damaj, 2009).
Nicotine inhibition of evoked DA release in the shell and the core of the NAc were
blocked by nAChR antagonists ex vivo. However, the NAc core, but not the NAc shell, was
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blocked by α-conotoxins, suggesting that nicotine’s effects are mediated by α6*-nAChRs.
Although it was previously determined that cholinergic interneurons excite presynaptic nAChRs
on DA terminals (M. T. Brown et al., 2012b; I. W. Jones, Bolam, & Wonnacott, 2001; K. C.
Yang et al., 2009; Zhang et al., 2009), we demonstrate here that acute nicotine administration
causes a decrease in evoked DA release in the NAc, as reported previously by others (Perez,
McIntosh, & Quik, 2013; Zhang et al., 2009). Under the previous model, direct activation of the
nAChR on the DA terminal would induce increased DA release, as a cationic influx into the
presynaptic terminal would induce a higher magnitude of vesicular release. However, our results
would suggest that there are interneurons regulating DA release in the NAc. It is likely that
nAChRs are present on the terminals of these interneurons that then modulate the release of DA
from DAergic neurons (Taylor, Steffensen, et al., 2013; K. Yang et al., 2011). Under this model,
activation of the nAChRs on the interneurons would decrease the level of evoked DA release
recorded by FSCV. Our experiments with the specific α6*-nAChR antagonists α-conotoxins in
both the NAc core and NAc shell demonstrate a distinct difference in the nAChR distribution in
these anatomical regions. Given that α-CtxMII completely blocks the effects of nicotine in the
NAc core and does not block the effects of nicotine in the NAc shell, yet DHβE completely
blocks the effects of nicotine in the NAc shell, these results indicate that the NAc core primarily
operates via α6*-nAChRs and the NAc shell primarily operates via α4β2 nAChRs. This verifies
the results of those previously reported (Exley, McIntosh, Marks, Maskos, & Cragg, 2012).

Ethanol Inhibits Dopamine Release Through nAChR Interactions
Given that ethanol has been shown to decrease evoked DA release, as measured by
FSCV, we sought to evaluate the role of ethanol on nAChRs in mediating evoked DA release in
the NAc in vivo and ex vivo, as we are not aware of any previous studies that have systemically
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focused on the involvement of ethanol inhibition via nAChRs at DA terminals. Local
stimulation in the NAc slice preparation produces a robust increase in DA release with a single
pulse, but evinces marked frequency modulation with multiple pulses, with optimal release at 20
Hz (10 pulses). Similar to nicotine, ethanol significantly decreased DA release at concentrations
20-160 mM and reduced phasic responses across all frequencies equally. Superfusion of the α7subunit specific antagonist MLA had no effect on ethanol inhibition of evoked DA release,
suggesting that ethanol is not acting in either the NAc core or NAc shell via α7*-nAChRs.
However, as α-CtxMII and α-CtxMII [H9A; L15A] significantly reduced ethanol inhibition of
DA release in the NAc core, this suggests that ethanol is acting via α6*-nAChRs in the NAc
core. Thus, as α-CtxMII significantly blocked both nicotine and ethanol in the NAc core, both
nicotine and ethanol appear to be acting via the same α6*-nAChRs. However, given that the
block of α-CtxMII was complete with nicotine and incomplete with ethanol, it is probable that
ethanol is acting through more than one mechanism in the NAc, whether intracellular or through
an extracellular receptor.
Ethanol reduced evoked DA release in vivo with an IC50 of 2.0 g/kg, a moderately
intoxicating dose level. We determined this IC50 of ethanol in vivo through previous
experimentation (data not shown). These studies provide the physiological relevancy of ethanol
inhibition of evoked DA release at terminals in the NAc. As α-CtxMII cannot be administered in
vivo, due to its inability to cross the blood brain barrier, we utilized i.p. administration of MEC to
block nAChRs. MEC blocked ethanol inhibition of evoked DA release, thus providing further
evidence that the mechanism of ethanol inhibition of DA release occurs through a nAChR
subunit. Comparing these physiologically-relevant results with our ex vivo experimentation, we
conclude that MEC is antagonizing the α6*-nAChRs in the NAc against the attenuation of
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ethanol. Given that α6*-nAChRs are located on GABA terminals and known to enhance GABA
release (K. Yang et al., 2011), it is possible that ethanol inhibition of evoked DA release results
from activation of α6*-nAChRs on GABA terminals that inhibit evoked DA release. However,
we acknowledge that the mechanism of nAChRs in the NAc may be much more complex due to
the compelling evidence of nAChRs present on DA terminals (Exley et al., 2012; Zoli et al.,
2002).
Interestingly, α6 knock-out mice fail to self-administer nicotine. However, once the α6
subunit is re-expressed via a lentiviral vector, the mice develop sustained acute selfadministration behavior (Pons et al., 2008). The VTA has α6*-nAChRs on presynaptic GABA
terminals, but not on the somata of the DAergic neurons (Taylor, Steffensen, et al., 2013; K. C.
Yang et al., 2009). Thus, nicotine can modulate both DA and GABA terminal neurotransmitter
release (Mansvelder, Keath, & McGehee, 2002; Yin & French, 2000), although the majority of
endogenous cholinergic inputs into the VTA appear to contact GABA rather than DA neurons
(Fiorillo & Williams, 2000; Garzon, Vaughan, Uhl, Kuhar, & Pickel, 1999). More specifically,
nAChRs play a crucial role in modulating GABA release onto DA neurons in the VTA (Taylor,
Steffensen, et al., 2013; K. Yang et al., 2011). The majority of GABA neurons in the VTA
express α4 and β2 nAChR subunits, which can be blocked by the non-competitive antagonist
MEC, or by the competitive antagonist dihydro-β-erythroidine hydrobromide (DHβE)
(Mansvelder et al., 2002). It is the emerging view that the early acute effects of nicotine in the
VTA predominantly affect GABA neurons, and that the nAChRs that have been associated with
these cells desensitize rapidly, leading to a long-lasting excitation (disinhibition) of DA neurons
through removal of the inhibitory influence of GABA (K. Yang et al., 2011). Recent optogenetic
studies have demonstrated that selective activation of VTA GABA neurons drives conditioned
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place aversion (Tan et al., 2012) and disrupts reward consumption (van Zessen et al., 2012),
providing compelling evidence for the importance of GABA neurons in regulating DA
transmission in the mesocorticolimbic reward pathway, and in particular interactions between
ethanol and nicotine reward signaling. Thus, GABA inhibition is a critical regulator of DA
neurotransmission in the mesocorticolimbic system and for the rewarding properties of both
ethanol and nicotine.

Ethanol Modulation of DA Release
Using voltammetry, we demonstrated that electrically-evoked, phasic DA release is
inhibited in a dose-dependent manner by moderate to high ethanol in ex vivo and in vivo
preparations, respectively. In consideration of the diverse effects of ethanol on mesolimbic DA
activity as measured by both microdialysis and voltammetry, we sought to address the
underlying mechanisms of ethanol’s actions on evoked DA release at terminals in the NAc by
examining ethanol’s effects in the presence of various GABAAR agonist and antagonists. As the
ex vivo preparation lacks the cell bodies of the projecting DA neurons and stimulation occurs
locally, this setup allows us to specifically examine the phasic release of DA at terminals.
Additionally, the in vivo preparation provides relevancy to the ex vivo preparation as afferent
pathways remain operational.
The exact mechanism by which ethanol enhances GABAAR-mediated responses remains
unclear. Ethanol potentiates GABA transmission in many brain areas (Siggins, Roberto, & Nie,
2005; Weiner & Valenzuela, 2006), and modulation of GABAergic synaptic transmission is still
regarded as one of the main factors underlying alcohol withdrawal-related phenomena (Liang &
Olsen, 2014). GABAARs undergo allosteric modulation by ethanol, anesthetics, benzodiazepines
and neurosteroids, and have been implicated in the acute as well as the chronic effects of ethanol,
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including tolerance, dependence and withdrawal [for a more complete review see (Enoch,
2008)]. We have reported in multiple studies that GABA neuron firing rate is inhibited by
GABAA and GABAB receptor agonists (Steffensen et al., 2000; S. H. Stobbs et al., 2004) and by
ethanol in rats in vivo with an IC50 of 1.0 g/kg (Kimberly H. Ludlow et al., 2009; Scott C.
Steffensen et al., 2009; S. H. Stobbs et al., 2004). These inhibitory effects on GABA neurons are
believed to contribute to ethanol’s excitatory effects on DA cell firing activity via disinhibition.
This is one mechanism wherein ethanol might enhance spontaneous DA release. However,
phasic DA release at terminals appears to be affected differentially. This may be due to GABA
neurons present in the VTA that project to the NAc and modulate the release of DA in the NAc
or GABA neurons in the NAc that influence phasic DA release through cholinergic interaction.
Since ethanol is known to influence neuronal excitability through direct inhibitory actions
on GLU NMDA receptors (Wang et al., 2007), we first tested the effects of the NMDA
antagonist APV on ethanol attenuated DA release. APV did not significantly affect ethanol
inhibition of DA release. Perhaps this is due to GLU inputs to the NAc that are not operational
on DA terminals, but on NAc MSNs or a cholinergic interneuron.

GABAA Receptor Pharmacology in the Nucleus Accumbens
Superfusion of the GABAAR agonist muscimol failed to alter DA release in the NAc at
the typical dose levels used to block GABAARs. Not until extremely high doses of muscimol
(350 µM) were superfused did effectiveness similar to ethanol become manifest. Additionally,
superfusion of the potent GABAA drugs CDX (30 µM) and pentobarbital (100 µM) had no effect
on inhibiting DA release in the NAc and did not alter the effects of ethanol inhibition of DA
release. The lack of effectiveness of muscimol, CDX, and pentobarbital led us to the possibility
of either an atypical GABAAR or a metabotropic GABABR responsible for the behavior of the
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DA neurons to ethanol. In order to determine if these other classes of GABA receptors are
involved in ethanol-mediated inhibition of DA release, we tested common GABAAR antagonists
to determine whether they could block the effects of ethanol. Surprisingly, we did not observe
any significant effect of either bicuculline or picrotoxin within the expected ranges of
concentration effectiveness.

GABAB Receptor Pharmacology in the Nucleus Accumbens
In order to identify whether GABABRs were sufficient for inhibiting DA release in the
NAc, we superfused the GABAB agonist baclofen at multiple concentrations (1 µM – 2 mM).
Baclofen did not demonstrate similar characteristics to ethanol inhibition of DA release at
customary doses, but did demonstrate a significant attenuation of DA release at 100 µM, a very
high dose considering that baclofen inhibits VTA GABA neurons with an IC50 of 1 μM.
CGP55845 (5-50 μM) demonstrated a robust increase of DA release and a significant block of
the effects of ethanol. As baclofen did not demonstrate a significant decrease of DA release, we
superfused the GABAB agonist SKF97541 (considered ten times more potent than baclofen) and
it had no effect on phasic DA release, suggesting that GABAB receptors were not involved in
ethanol inhibition of DA release at terminals in the NAc.
Due to the lack of effect from stereotypical GABAAR agonists and antagonists and the
lack of effect of GABABR agonists, we examined the effects of GABA itself on DA release
under multiple pulse stimulation conditions. We tested the effects of GABA on terminal DA
release through a very broad concentration spectrum (100 nM – 10 mM). Interestingly, GABA
only reduced DA release at 10 µM and at extremely high concentrations (3 – 10 mM), suggesting
that the GABAARs mediating ethanol inhibition of DA release might contain ρ-subunits, which
are not very sensitive to GABA. These subunits are characterized by insensitivity to the
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GABAAR antagonist bicuculline, resistance to the GABABR agonist baclofen, and lack of
response to the GABAAR modulators, benzodiazepines, barbiturates, and neurosteroids (R. M.
Woodward, Polenzani, & Miledi, 1993), which is consistent with our findings. However, as ρsubunits are typically homomeric GABAAρ receptors, which is characteristic of those found in
the retina, we did not consider this as a viable direction for our study. However, it has been
previously reported that α4β3δ GABAARs have distinct pharmacology, are insensitive to
modulation by benzodiazepine ligands, and neurosteroid effectiveness is greatly enhanced at
α4β3δ (N. Brown, Kerby, Bonnert, Whiting, & Wafford, 2002). Thus, we determined to explore
the effects of the δ-subunit for GABAAR pharmacology in the NAc.

Effectiveness of Ethanol on the δ-subunit of the GABAA Receptor
With the previous effectiveness of Ro15-4513 on ethanol consuming WT mice (Melon &
Boehm, 2011), we determined to superfuse this antagonist as it would selectively block
GABAAR δ-subunits. The competitive antagonist, Ro15-4513, effectively blocked ethanol
inhibition of DA release both ex vivo and in vivo, with no effect on its own to the baseline signal,
suggesting the involvement of δ-subunit GABAARs. Although its direct effects on alcohol
behavioral antagonism remain controversial, Ro15-4513’s receptor interactions with ethanol
include δ-subunit containing GABAARs [for review see Wallner and Olsen (2008)]. To further
elucidate the role of δ-subunits in ethanol DA inhibition, we examined ethanol’s effects on DA
release in NAc slices of δ-/- mice. Our results strongly demonstrate that δ-/- mice have increased
phasic DA release after ethanol superfusion compared to WT mice, further implicating GABAA
δ-subunits in ethanol’s inhibitory effects on evoked DA transmission. With this solid evidence
confirming δ-subunit GABAAR involvement, we tested the δ-subunit selective agonist THIP to
demonstrate its effectiveness to agonize the receptor similar to ethanol. Surprisingly, THIP had
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no effect on DA release at the expected dose ranges for δ effects, even though THIP has higher
efficacy at α4β3δ GABAARs than GABA (N. Brown et al., 2002) and dramatically increased
THIP sensitivity (Meera, Wallner, & Otis, 2011).

Effects of Neurosteroids in Attenuating the Effects of Ethanol at GABAA Receptors in the Nucleus
Accumbens
The δ-subunit is responsible for neurosteroid sensitivity (Wohlfarth, Bianchi, &
Macdonald, 2002) and alcohol sensitivity (Hanchar, Dodson, Olsen, Otis, & Wallner, 2005).
Extrasynaptic δ subunit-containing GABAARs show distinct pharmacology, including low
efficacy to GABA, and high sensitivity to positive modulation by neurosteroids, ethanol, and
general anesthetics (Olsen & Sieghart, 2008). Thus, as ethanol and neurosteroids demonstrate
similar selectivity on -containing GABAARs, neurosteroids might provide further insight into
the effects of ethanol on the GABAAR subtypes modulating the release of DA in the NAc.
Superfusion of the neurosteroid ALLO (20 μM), a potent positive allosteric modulator of
GABAARs, significantly blocked ethanol inhibition of DA release. Superfusion of Trilostane (20
μM), an inhibitor of the enzyme 3β-hydroxysteroid dehydrogenase (an enzyme that raises
endogenous release of DHEAS), also significantly attenuated the effects of ethanol inhibition of
DA release. In addition, superfusion of DHEAS (10 μM), a negative allosteric modulator of the
GABAAR, had a slight excitatory effect on DA release and significantly attenuated the effects of
ethanol inhibition of DA release. Thus, given the sensitivity of the GABAA δ-subunits to
neurosteroids, this data further demonstrated the likelihood of a δ-subunit being expressed in the
GABAAR present in the NAc.
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Confirmation of an Atypical GABAA Receptor in the Nucleus Accumbens
With pharmacological and molecular evidence in support of the presence of a δ-subunit
containing GABAAR modulating DA release with the effects of ethanol both ex vivo and in vivo,
it was necessary to explore the lack of response of the GABAAR to THIP, a potent δ-subunit
GABAAR agonist. Previous published data indicated that THIP is weakest at ρ1-subunits
(Kusama et al., 1993). As mentioned previously, a search of the literature revealed that
GABAAρ receptors are characterized by insensitivity to the GABAAR antagonist bicuculline,
resistance to the GABABR agonist baclofen, and lack of response to benzodiazepines,
barbiturates, and neurosteroids (R. M. Woodward et al., 1993). Given that our δ-subunit
pharmacology did not give us the expected results with THIP, we determined to explore the
possibility of an atypical GABAAR with a ρ-subunit. GABAAρ receptors are expressed in many
brain regions, and it has recently been theorized that GABAA ρ-subunits would soon be
discovered in the caudate with the possibility of, “a co-assembly of GABA ρ with GABAA
subunits, which would mask the typical GABAρ pharmacology” (Martinez-Delgado et al.,
2010). Also, due to high sequence conservation between ρ- and β-subunits, this “may account
for some GABA receptors in the CNS that exhibit atypical characteristics” (Milligan et al.,
2004). Our high correlation to these characteristics of ρ-subunits (except the neurosteroids) and
recent publications indicating a possibility of ρ-subunits in the caudate, we felt confident
pursuing GABAA ρ-subunit pharmacology. Referencing the Allen Brain Atlas which
demonstrates in situ hybridization of RNA expression, we noted a significant distribution of
GABRR1 (ρ1-subunit) in the ventral striatum (Lein et al., 2007), indicating that somata in this
region are expressing ρ1-subunit mRNA.
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Superfusion of the selective, competitive ρ1 antagonist TPMPA demonstrated a moderate
increase of DA release on its own and a complete block of ethanol inhibition of DA release. In
addition to this positive data on attenuating the effects of ethanol on DA release, we confirmed
our results with immunohistochemistry, successfully identifying neurons in the NAc that
selectively express ρ1-subunits. Similar to the δ-subunit pharmacology, we wanted to confirm
our ρ1-subunit findings pharmacologically with a specific ρ1 agonist; however, the pharmacology
for ρ1-subunits is not specific and precluded us from pursuing this direction.
In consideration of the α-subunit present in the GABAAR expressed in the NAc, we
examined our benzodiazepine and barbiturate data. The α-subunits most sensitive to
benzodiazepines are α1, α2, α3, and α5; the α-subunits that are benzodiazepine-insensitive are the
α4 and α6 subunits (Luscher, Baur, Goeldner, & Sigel, 2012). Thus, with our data demonstrating
the insensitivity of this GABAAR to the benzodiazepine CDX, the likely α-subunits would be
either α4 or α6. However, barbiturates are most sensitive at the α6 subunit (Fisher & Fisher,
2010) and our superfusion of pentobarbital demonstrated a lack of sensitivity to this barbiturate.
Thus, the most likely α-subunit candidate for the GABAAR in the NAc would be the α4-subunit.
Given the previous published data expressing the high sequence similarity of ρ- and β-subunits,
we propose an atypical GABAAR in the NAc that modulates DA release consisting of two α4subunits, two ρ1-subunits, and a δ-subunit (α4ρ1δ). According to our understanding, this is the
first proposed atypical GABAAR of this type in the nervous system. This proposal is strongly
supported by pharmacological, molecular, and immunohistochemistry data, in addition to
multiple recent publications hinting toward the possibility of an atypical GABAAR in the
caudate. We have demonstrated that this atypical GABAAR is directly involved in ethanol’s
inhibitory effects on DA transmission in the NAc.
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As we examined GABABR agonists and antagonists as well as atypical GABAAR
agonists and antagonists, a clear picture began to formulate regarding the atypical characteristics
that are unique to GABA receptors in this region of the brain. With support from previously
published research, we were able to identify a plausible hypothesis and re-direction regarding the
ρ1-subunit integrating in the GABAAR (Milligan et al., 2004) in place of the typical β-subunit
(Martinez-Delgado et al., 2010). In addition to in situ hybridization data demonstrating ρ1subunits being present in the NAc (Lein et al., 2007), our own immunohistochemistry evidence
clearly demonstrated the presence of the ρ1-subunit, further confirming our pharmacology data of
both δ- and ρ1-subunits regulating DA release in the NAc.

Baicalein
Previous experimentation with baicalein has demonstrated neuroprotective (Mu, He,
Yuan, Li, & Du) benefits as well as anti-inflammatory (Li, Wang, Pei, Liu, & Hong, 2005),
antitumor (Chao, Su, & Liu, 2007), and antioxidant effects (Huang, Lee, Chien, & Chou, 2005)
in neurons when exposed to various toxins and addictive drugs (Y. Liu et al.; F. Q. Li et al.; Wu
et al.; Mu et al.; Cheng et al.). Given its promising characteristics and possible mechanisms of
action, ethanol studies with baicalein were requisite.
We initially tested the effects of baicalein ex vivo, however we discovered significant
solubility issues. When we initially dissolved baicalein in DMSO (0.1 – 3 %), we would lose our
FSCV signal as a result of the DMSO. We then attempted to solubilize baicalein with the
solvent propylene glycol. Unfortunately, we did not obtain complete solubility in reasonable
ranges (1 – 20 %). With our preliminary attempts with baicalein (50 µM) incompletely
solubilized, we did see significance of attenuating ethanol’s inhibition of DA release. However,
in order to know the proper concentration of baicalein, we needed to solve the solubility issues.
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We obtained a soluble metabolite of baicalein, baicalin hydrate, and attempted our
experimentation. To our dismay, we soon realized that we could not properly record the results
of DA release with baicalin hydrate as baicalin hydrate has a redox potential at the same voltage
as DA. Thus, the oxidation of baicalin hydrate was masking the true effects caused by both
baicalin and ethanol.
We determined to verify our preliminary findings ex vivo with baicalein administration in
vivo. Dissolving baicalein in DMSO (3 %) and administering IP 30 minutes prior to ethanol (2
g/kg) and controlling for vehicle, we demonstrated that baicalein significantly attenuates the
ethanol inhibition of DA release in the NAc. Thus, baicalein could be a possible nutraceutical
intervention in alleviating the effects of acute ethanol in humans. We recognize that the acute
exposure is much different from the chronic exposure (the addictive state). However, this data
representing significance in the NAc under acute exposure allows us to further pursue baicalein
effects in vivo in both the chronic non-dependent and withdrawal states of alcohol addiction.
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CHAPTER 5: Conclusions
These studies demonstrate an extensive look into the complex ethanol inhibition of DA
release at terminals in the NAc. It has been stated that one that understands ethanol, understands
the brain. The reason for this statement is due to the unrestrained nature of ethanol – it is capable
of causing effects on multiple ionotropic receptor subtypes (i.e. acetylcholine, glutamate, and
GABA receptors) in the nervous system and can affect systems both extra- and intracellularly as
the molecule is small enough to diffuse through the cellular membrane. Thus, we recognize that
even though this project has pharmacologically explored the extracellular effects of ethanol
inhibition of DA release in the NAc, it is possible that DA release in the NAc can be affected by
intracellular mechanisms as well.
Our study began with proposed experiments that hypothesized GABA inhibition of DA
release in the NAc with the assumption that stereotypical GABAA agonists would produce
similar effects to ethanol with its inhibition of DA release and that stereotypical GABAA
antagonists would effectively block the inhibitory effects of ethanol of DA release. However,
the results of these stereotypical GABAA agonists (including benzodiazepines and barbiturates)
and antagonists quickly demonstrated to us that ethanol was acting via atypical GABAAR
subunits or possibly through GABABRs. In addition, we recognized an important correlation of
co-dependence between alcohol and nicotine and determined to explore the possibilities of both
ethanol and nicotine acting through similar subunits in the NAc to modulate DA release. Thus,
we began to explore these options further and it opened up a greater depth of understanding of
the complexity of this modulatory system present in the NAc.
As we examined the effects of nicotine on DA release, we were surprised by the fact that
nicotine caused an inhibition to the DA release similar to ethanol. As others have proposed
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Figure 18: Proposed Hodology of GABA Modulation of DA Release in the Nucleus Accumbens. Given
the results of these studies, we propose the above model of neuronal organization and modulation of DA
release by GABA in the NAc. A cholinergic interneuron (CIN) residing in the NAc contains the atypical
GABAAR at dendritic or somatic sites. In addition, α6* nAChR is located on the VTA projecting GABA
terminal. Thus, activation of the α6* nAChR by nicotine would cause increased GABA release and thus
attenuated DA release in the NAc. In addition, activation of the atypical GABAAR on the CIN would
hyperpolarize the neuron and decrease DA release in the NAc.

nAChRs on DA terminals due to cholinergic interneurons (Cachope et al., 2012), activation of
these nAChRs with nicotine would cause an increase of DA release due to the influx of Na+ into
the DA terminal. Although the resultant inhibition could be due to desensitization of the
nAChR, this would be unlikely at the nicotine concentrations that were being superfused. We
soon discovered that both nicotine and ethanol act similarly in the NAc and are blocked in the
core by superfusion of the α6*-specific nAChR antagonist α-CtxMII. Interestingly, whereas the
effects of nicotine were completely blocked with α-CtxMII in the NAc core, the effects of
ethanol were only partially blocked with α-CtxMII. This would indicate that ethanol is acting
through activation at the nAChR as well as through other mechanisms, whether intra- or
extracellularly.
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These experiments verify that both nicotine and ethanol reduced phasic release of DA in
the NAc, and that α6*-nAChRs and an atypical GABAAR are involved in ethanol inhibition of
evoked DA release in the NAc of C57/BL6 mice. Although these findings of an atypical
GABAAR is confirmed only at this time in a mouse model and direct correlation to human
subjects cannot be inferred, it is important to recognize that this finding when published will
promote exploration into further GABAAR pharmacology in the NAc in both mouse and human
models. In addition, the mouse model is widely used in neuroscience research as there are high
correlations between the neural networks and constructs between human and mice. Additional
confirmation of these findings will perpetuate scientific thought, research, and development and
ultimately will lead to improved clinical therapeutics for those suffering with the disease of
addiction, especially related to alcohol dependence / co-dependence.

Future Directions
Given the results of these studies, it would be logical to follow these acute ethanol
exposure studies with those of chronic ethanol to verify how the ethanol inhibition of DA release
is altered in the NAc and to verify whether GABA neurons are up-regulated in the NAc as we
have seen in the VTA. As rodents fail to self-administer ethanol to the state of dependence,
these chronic ethanol studies will be performed by placing rodents (C57/BL6 and δ-/-) into vapor
chambers that will supply the rodents with vaporized ethanol for 16 hours / day on a four day /
three day on-off cycle. After the withdrawal period of three days, the rodents will be placed into
individual chambers and will be given the election of consumption of 30 % ethanol or water
(“Drink-in-the-Dark procedure”). The consumed volume of each liquid will be measured for
analysis. After a dependent state of ethanol is developed by the rodents (usually after five
weeks), the rodents will be sacrificed and FSCV analysis both ex vivo and in vivo will be
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performed as described previously in our methods given our expected pharmacology
characteristics. The pharmacological data can then be statistically analyzed against the acute
data to verify induced changes to the atypical GABAARs modulating DA release in the NAc.
As there is a suspected interneuron expressing ρ1-subunits in the NAc (Fig. 15),
immunohistochemistry of acetylcholine neurons and GABRR1 can be utilized in a CD-1 GAD
GFP mouse to verify whether the ρ1-subunits are present on the suspected cholinergic
interneuron (M. T. Brown et al., 2012a; Cachope et al., 2012) that has been shown to modulate
DA release in the NAc or whether there are other interneurons involved in the synaptic
hodology. This study will further elucidate the relationship of this interneuron to the GABA
inhibition of DA release in the NAc.
For complete hodology confirmation, transmission electron microscopy (TEM) can be
utilized with immunogold staining and silver enhancement to verify the presence of GABA
terminals on DA terminals, or GABA terminals on cholinergic interneurons that then send a
modulatory projection to DA terminals. This is a highly ambitious study and was undertaken for
a few months by myself and a couple of other researchers. However, we acknowledge that this
project will take a few years to successfully implement and will require additional expertise. We
propose collaboration with one skilled in TEM and in TEM immunohistochemistry in order to
obtain images that can confirm the presence of each of these hypothesized neural pathways.
Additional studies examining ethanol pharmacological activity on DA release in the NAc
may provide novel mechanisms for testing ethanol pharmacotherapies, such as baicalein. The
isoflavone baicalein demonstrated significant results in counteracting the acute effects of ethanol.
As baicalein was only tested in the acute condition, baicalein must also be tested in both the
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chronic non-dependent and withdrawal states. Promising results in this regard would propel
baicalein forward as a candidate for alcohol addiction therapy.
Ultimately, this study provides unique insight into the complex regulation of DA release
in the NAc via complex hodology and atypical receptor subtypes. As the dopaminergic systems
of the nervous system are limited to confined regions in the brain and are important for behaviors
such as motivation, reward, arousal, cognition, and movement, it would seem logical that the
brain would regulate these dopaminergic systems in a different manner than other systems (i.e.
glutamatergic and cholinergic) in order to maintain more precise and coordinated control.
Disruption to homeostasis of these dopaminergic systems results in complicated disorders such
as: Parkinson’s disease, addiction, schizophrenia, and attention deficit hyperactivity disorder.
Thus, as research continues in the field of neuroscience similar to the studies of this dissertation,
we will become more aware of the fine-tuned capabilities of the nervous system to regulate DA
release and will develop an understanding of how we can apply therapeutic applications to these
disorders in a manner that does not disrupt other systems (i.e. side-effects).
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